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ABSTRACT 
 Dengue virus (DENV) is a mosquito-borne virus of global concern that leads to 
infections with symptoms ranging from high fevers and headaches to death.  Current 
estimates place almost half the world’s population living in areas that are at-risk for 
infection by dengue and that area continues to expand over time.  There are four 
distinct serotypes of dengue (DENV1, DENV2, DENV3, and DENV4).  Disease severity 
from dengue infection is significantly worse if there is a secondary infection by a 
heterotypic serotype.  The problems of increased severity with secondary infection as 
well as host immune response evasion by the virus itself have made vaccine 
development especially difficult. 
Analysis of complete polyprotein sequences of all four DENV serotypes revealed 
that all serotypes are currently subject to ongoing purifying selection and have 
experienced past purifying selection.  However, several noteworthy exceptions within 
some genes of varying serotypes suggest conflicting evolutionary pressures.  Most 
notably, the envelope (E) gene of DENV4 showed nucleotide polymorphism patterns 
suggestive of positive selection or relaxed purifying selection in its epitope regions.  The 
E protein interacts directly with the host cell and is necessary for viral entry suggesting 
that its polymorphism pattern is indicative of evasion from immune system recognition.  
Both the NS1 gene of DENV2 and NS3 gene of DENV3, which are critical in viral 
replication, exhibited significantly higher medians of nonsynonymous gene diversity in 
vi 
their epitope regions implying escape mutations in these proteins as well.  Significant 
conflicting ratios of πN (mean nonsynonymous nucleotide diversity) to πS (mean 
synonymous nucleotide diversity) between pairs of serotypes indicate that each 
individual serotype is under conflicting evolutionary pressures and help to explain the 
severity of secondary heterotypic infections. 
A comparison of three epitope prediction applications using datasets of both 
DENV genomes coupled with known cytotoxic T lymphocytes (CTL) DENV epitopes 
revealed significant differences in RANK and sensitivity measures of the programs.  As 
these programs are used to predict which epitopes should be further studied in the 
creation of subunit vaccines, it was apparent that applications containing a combination 
of several prediction methods in concert are much more efficient than programs 
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The use of bioinformatics in immunology has become one of the most rapidly 
evolving fields in biology today.  Recent advances in technology coupled with 
appreciable interest in preservation of human life have created a tremendous increase 
in the number of viral genomes available for analysis and the tools with which to study 
them.  Using a combination of statistical and computational techniques, it is possible to 
quantify changes between individual viral genomes, infer phylogenetic and ancestral 
relationships, predict host immune response, and complete a plethora of other analyses 
(Volz et al., 2013).  As viral infections are typically more difficult to treat in comparison 
to bacterial infections and have higher rates of mutation, these analyses may be able to 
assist in the treatment and prevention of viral illness (Volz et al., 2013). 
The major histocompatibility complex (MHC) found in all vertebrates is the 
primary adaptive immune response to viral infection (Andersen et al., 2006; Dimmock et 
al., 2007; Hughes and Yeager, 1998).  Nucleated somatic cells express MHC class I 
molecules which consist of proteins that either identify the cell as belonging solely to 
the host (self) or as being bound to a foreign peptide (nonself) (Andersen et al., 2006; 
Dimmock et al., 2007; Hughes and Yeager, 1998).  This presentation of a foreign peptide 
by the MHC on an antigen presenting cell (APC) is called an epitope (Dimmock et al., 
2007).  Cytotoxic T lymphocytes (CTL) have a T cell receptor (TCR) that recognizes these 
 
2 
epitopes and elicit several responses (Andersen et al., 2006; Dimmock et al., 2007).  
These responses include proliferation of T cells, differentiation into memory or effector 
T cells, and the eradication of the infected cell (Andersen et al., 2006; Dimmock et al., 
2007).  
Considering viruses, RNA viruses are particularly poised to evade immune system 
recognition in order to replicate and proliferate as much as possible.  RNA viruses have 
higher mutation rates, estimated rates of mutation being on the order of 10-3 to 10-5 per 
10Kb genome, than those of DNA viruses (Domingo and Holland, 1997; Drake et al., 
1998; Hughes and Hughes, 2007).  This is most likely due to the fact that RNA 
polymerase, RNA replicase, and RNA transcriptase are not nearly as efficient as their 
DNA counterparts resulting in many errors when replication occurs (Domingo and 
Holland, 1997). 
Utilizing sequence data of RNA viruses, patterns in nucleotide polymorphism, 
particularly at the population level, can give insight to which mechanisms of selection 
may be acting on various proteins and known epitope regions within the virus’ genome 
(Hughes and Hughes, 2007; Lambkin et al., 1994; Moore et al., 2002; Rodriguez-Roche 
and Gould, 2013; Suzuki, 2006).  One of the most prevalent patterns is the mean 
number of synonymous substitution per synonymous site (dS) exceeding the mean 
number of nonsynonymous substitutions per nonsynonymous site (dN) as most 
nonsynonymous changes can disrupt function of the resulting protein and are typically 
deleterious therefore this pattern is evidence of purifying selection (Graur and Li, 2000; 
Kimura, 1977).  There are several studies showing evidence of purifying selection in viral 
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populations (Holmes, 2003; Hughes and Hughes, 2007).  While many nonsynonymous 
mutations are deleterious, this does not apply to all nonsynonymous mutations and it is 
possible for some that are only slightly deleterious to persist in populations (Ohta, 
1973).  Epitope regions of viruses would benefit immensely from retaining slightly 
deleterious variants leading researchers to search for patterns of positive selection (Bedi 
et al., 2013; Murray et al., 2013; Ross et al., 2002). 
A particular RNA virus of increasing international concern is the mosquito-borne 
Dengue virus (DENV).  DENV is both positive sense and single-stranded RNA with a 
genome that is a little over 10Kb in length (not including any untranslated regions) that 
encodes for one large polyprotein (Fields et al., 2013).  This polyprotein is eventually 
cleaved into eleven products.  Three are structural proteins:  AnchC (capsid), prM 
(precursor/membrane), and E (envelope); while eight are nonstructural and play several 
different roles:  NS1, NS2A, NS2B, NS3, NS4A, 2K, NS4B, and NS5 (Fields et al., 2013).  Of 
these proteins, E, NS3 and NS5 have been shown to be particularly important in viral 
entry into the cell and successful replication (Iglesias et al., 2014).  The E protein is 
necessary for viral entry into host cells while NS3 is particularly integral in RNA 
replication (Iglesias et al., 2014).  NS5, while also essential to RNA replication, has the 
ability to block interferon (Iglesias et al., 2014).  
With a primary DENV infection the epitope portions of the virus itself are 
recognized and consequently bound by TCR eventually leading to clearance of the 
infection after a short illness that is termed dengue fever typically with some symptoms 
resembling those to influenza (Dimmock et al., 2007, p. 197).  Dengue fever conveys 
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symptoms that are similar to those experienced with a case of influenza.  However, 
there is a much more drastic response to secondary DENV infections if the subsequent 
infection is that of a heterotypic serotype (World Health Organization, 2012a).  The 
illness that results from these secondary infections is termed dengue hemorrhagic fever 
or severe dengue and will be accompanied by several serious symptoms (World Health 
Organization, 2012a).  If these symptoms are left untreated, the illness may progress to 
dengue shock syndrome which ultimately results in death in up to 20% of cases (World 
Health Organization, 2012a). 
There are three prominent hypotheses regarding the mechanism behind the 
severity of secondary heterologous infection that patterns in the genome of nucleotide 
and gene diversity may help support or refute.  Suppose CTLs generated during primary 
infection resurface when a secondary serotype is presented.  However, these CTLs have 
a difficult time discerning cells that are infected with the secondary serotype as its 
sequence differs ever so slightly from the initial infection.  These CTLs may not bind as 
well or even at all to peptides presented by class I MHC in the newly infected cells 
(Vaughan et al., 2010).  This theory is termed original antigenic sin and it is thought to 
lead to higher viral loads (Halstead et al., 1983; Vaughan et al., 2010).  Another very 
similar theory is known as altered peptide ligand (APL) antagonism. 
APL antagonism occurs when there are slight changes in the secondary 
infection’s RNA sequence that alter the epitope presented to TCR by an infected cell 
(Jameson and Bevan, 1995).  CTLs will still bind to the antigen presenting cell but will not 
elicit an immune response.  Instead, the interaction may cause the T-cell to become 
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entirely functionally inactive or allow for only partial activation which also allows for a 
higher viral load (Andersen et al., 2006; Kalergis and Nathenson, 2000; Sloan-lancaster 
and Allen, 1996).  
Antibody-dependent enhancement is somewhat similar to the two previous 
concepts except that in this phenomenon replace CTLs that do not recognize 
heterotypic serotypes well with antibodies that are produced during a primary infection 
(Kliks et al., 1989; Vaughan et al., 2010; Whitehead et al., 2007).  The antibodies from 
the primary infection bind to the new DENV particles and remain bound although are 
unable to neutralize the virus (Kliks et al., 1989; Vaughan et al., 2010; Whitehead et al., 
2007).  This complex then attaches to fragment, crystallizable regions of monocytes, 
allowing the DENV particles to enter the white blood cell and replicate also creating an 
increased viral load (Kliks et al., 1989; Vaughan et al., 2010; Whitehead et al., 2007). 
As the prevention and control of DENV is of increasing concern, creation of a 
vaccination that would generate immunity for all four serotypes without causing 
adverse reactions is of extreme interest.  The discovery of vaccinations has changed 
widely since Jenner’s initial vaccine to smallpox (Hilleman, 2000).  Employing genomes 
and computer algorithms along with known immunological data has brought about a 
more efficient process in vaccine creation by allowing for identification of possible 
epitopes that can be used to assist the production of effective subunit vaccines (De 
Gregorio and Rappuoli, 2012; Delany et al., 2014; Gilbert, 2011; He et al., 2010; 
Hilleman, 2000; Yang and Yu, 2009).  Epitope prediction applications use various 
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methods in order to predict which will have the most significant response and range 
widely in their efficacy (De Gregorio and Rappuoli, 2012; Yang and Yu, 2009). 
Two separate studies were performed to compare gene and nucleotide diversity 
within and between DENV serotypes and to evaluate the performance of three epitope 
prediction applications.  The first study was an analysis of a large dataset of 1615 whole 
DENV genomes.  This study examined the patterns of both nucleotide polymorphism 
and gene diversity in all eleven proteins of all four serotypes.  Patterns within CTL 
epitope regions were compared to those in non-epitope regions in order to detect 
immune evasion between serotypes as secondary heterotypic infections tend to be 
more severe and elicit little to no immune response.  The second study employed 
portions of the larger DENV dataset and known epitopes from the initial study to 
compare scores given to predicted epitopes from three epitope programs in both RANK 
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The Dengue virus (DENV) is a positive-sense, single-stranded RNA virus classified 
in the Flavivirus genus.  This genus contains several detrimental viruses including Yellow 
Fever virus for which the genus is named and the West Nile virus among others (Kuno et 
al., 1998).  The majority of the members of the Flavivirus genus are transmitted via 
arthropod vectors where DENV is of immense concern as it is currently the most rapidly-
spreading mosquito-borne virus in the world (World Health Organization, 2012b). 
DENV infection results in the onset of dengue fever (DF) which conveys flu-like 
symptoms and is typically remedied over a period of several days without much medical 
intervention, however, DENV infection may also produce a more critical disease known 
as dengue hemorrhagic fever (DHF) that is characterized by petechial hemorrhaging, 
high fever, and thrombocytopenia (Rodriguez-Roche and Gould, 2013; World Health 
Organization, 2012b).  The severity of DHF is distinguished by plasma leakage.  If not 
successfully treated when signs of circulatory failure appear DHF can progress to dengue 
shock syndrome (DSS) which can cause respiratory distress and organ impairment due 
to excessive plasma leakage and fluid accumulation and can culminate in death (World 
Health Organization, 2012a). 
The DENV genome codes for one single polyprotein that is eventually cleaved 
into 11 major products, three of which are primarily structural:  AnchC (capsid), prM 
(precursor/membrane), and E (envelope); while the other eight are nonstructural:  NS1, 
NS2A, NS2B, NS3, NS4A, 2K (sometimes denoted as a fragment of NS4A), NS4B, and NS5 
(Fields et al., 2013).  There are four distinct serotypes of DENV denoted DENV1, DENV2, 
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DENV3, and DENV4 that differ by approximately 30-35%.  Secondary infection with a 
heterologous serotype is more likely to cause DHF/DSS (Rodriguez-Roche and Gould, 
2013; World Health Organization, 2012b).  Due to the difficulty of a secondary infection 
causing increased likelihood for disease, a vaccine for DENV is not currently available 
although there are recently completed trials of a potentially successful tetravalent 
vaccine (Durbin et al., 2013).  There are several theories as to how heterotypic infection 
results in increased disease severity rather than inferring a stronger host immune 
response (Goncalvez et al., 2007; Halstead, 1979; Halstead et al., 1983; Kliks et al., 1989; 
Whitehead et al., 2007). 
Typically, adaptive immune responses to viruses elicit class I major 
histocompatibility complex (MHC) molecules in the infected cells of vertebrates to bind 
foreign peptides and present them extracellularly (Hughes and Yeager, 1998).  These 
presented peptides are known as epitopes (Dimmock et al., 2007).  Epitopes are 
recognized by T cell receptors (TCR) of cytotoxic T lymphocytes (CTL) which initiate the 
destruction of infected cells (Hughes and Yeager, 1998).  In the case of DENV, this 
immune response works well with the initial infection yet poses significant health issues 
with a secondary heterotypic infection.  As immune response to viral infection is 
increasingly important to vaccine development, the epitope glycoproteins presented by 
class I MHC molecules that are recognized by CTL are therefore of the utmost 
importance in predicting epitopes and designing vaccines particularly in silico (Patronov 
and Doytchinova, 2013).   
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Patterns in nucleotide polymorphism of RNA viruses can be utilized to postulate 
how evolution may be acting on these epitope regions such as escape from immune 
system recognition or shed light on differences between serotypes, either of which may 
lead to more knowledge regarding the difficulties associated with secondary 
heterologous infection (Hughes and Hughes, 2007; Lambkin et al., 1994; Moore et al., 
2002; Rodriguez-Roche and Gould, 2013; Suzuki, 2006).  In protein-coding nucleotide 
sequence data the number of synonymous substitutions per synonymous site (dS) and 
the number of nonsynonymous (amino acid-altering) substitutions per nonsynonymous 
site (dN) are valuable indicators for revealing the mechanism of selection (Graur and Li, 
2000; Hartl, 2000; Hughes, 1999; Kimura, 1994; Nei, 1975).  The prevalent pattern 
displayed in the majority of these coding regions is that of mean dS exceeding mean dN 
This pattern is indicative of past purifying selection and is due to the fact that coding for 
a different amino acid with a nonsynonymous mutation can lead to disruptions in the 
creation of the resulting protein and are typically deleterious in nature (Graur and Li, 
2000; Kimura, 1977).  Not all nonsynonymous mutations are strongly deleterious, 
therefore slightly deleterious variants may persist within populations (Ohta, 1973).  
Patterns of positive selection may be found in epitope regions as slightly deleterious 
variants could be selected for in attempts to evade immune system recognition. 
As the severity of a secondary heterotypic DENV infection is of increasing global 
concern, the objective of the present study was to analyze patterns of both gene 
diversity and nucleotide polymorphism in known CTL epitope regions as well as to 
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further examine the similarities and differences within and amongst complete genomes 
of all four serotypes of DENV. 
2.2. Methods 
2.2.1 Sequences and epitopes analyzed 
Complete unaligned genome sequences of 1615 DENV isolates (640 of DENV1, 
598 of DENV2, 341 of DENV3 and 36 of DENV4) were obtained from the Dengue Virus 
Database available at http://www.denguedb.org/index.asp (Viral Bioinformatics 
Resource Center, 2009).  Artemis was utilized to arrange sequences into the correct 
reading frame (Rutherford et al., 2000).  Sequences were aligned at the amino acid level 
using ClustalW (Thompson et al., 1994) within the MEGA6 program’s Alignment Explorer 
(Tamura et al., 2013).  Aligned protein sequences were superimposed back onto their 
nucleotide frames.  Sequences with premature stop codons or indeterminate 
nucleotides were excluded from analysis (for a list of all utilized GenBank accession 
numbers see Table A.1). 
Known epitopes were obtained from the Immune Epitope Database and Analysis 
Resource available at http://www.iedb.org/ (Vita et al., 2010).  Epitopes used were 
limited to those presented by MHC Class I and found only in humans.  B cell epitopes 
and those listed as epitope containing regions were also excluded as CTL epitopes have 
been noted as especially important in immunity in several studies of dengue 
pathogenesis (Piazza et al., 2014; Vaughan et al., 2010; Weiskopf et al., 2013; Yauch et 
al., 2009).  525 of the remaining epitopes were 100% conserved within at least one of 
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the sequences within our DENV dataset (Table A.2).  It is of note that some epitopes 
were located either overlapping or entirely within other epitopes. 
2.2.2 Ancestral reconstruction 
A neighbor-joining (NJ) tree (Saitou and Nei, 1987) of all 1615 DENV isolates was 
constructed using the PAUP* program, version 4.0 (Swofford, 2003), rooted with the 
DENV4 serotype.  The bootstrap method (Felsenstein, 1985) was used with 1000 
bootstrap replicates in order to verify statistical significance of internal branches (tree 
not shown).  The NJ tree was imported into MEGA6 (Tamura et al., 2013) where the last 
common ancestor for each of the four serotypes was reconstructed using maximum 
parsimony (Eck and Dayhoff, 1966; Fitch, 1969).  Each of the reconstructed ancestors 
was then inspected for presence of the 525 aforementioned epitopes that were 100% 
conserved within our dataset. 
2.2.3 Nucleotide and gene diversity 
Epitope and non-epitope domains were differentiated in MEGA6 (Tamura et al., 
2013) for each serotype separately as not all CTL epitopes were found in all four 
serotypes.  These domains were then utilized in estimating dS and dN values by the 
Pamilo, Bianchi, and Li method (Li, 1993; Pamilo and Bianchi, 1993) within the MEGA6 
software (Tamura et al., 2013).  These values were used to then determine both the 
synonymous nucleotide diversity (πS), the mean of all dS values, and the nonsynonymous 
nucleotide diversity (πN), the mean of all dN values.  Statistical methods that did not rely 
on model dependence were used in order to avoid the assumptions that model-based 
methods have regarding various mechanisms of evolution (Hughes et al., 2006).  Ratios 
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of πN to πS were computed for each serotype separately.  These ratios were then 
compared by examining the differences between pairs of serotypes utilizing the known 
CTL epitope as the unit. 
Gene diversity was estimated using PolyAna (Knapp et al., 2011) for polymorphic 
synonymous and nonsynonymous nucleotide sites for epitope and non-epitope domains 






where n is the number of alleles and xi is the population frequency of the ith allele (Nei, 
1987, p. 177).  Any site at which nucleotide polymorphism could be considered either 
synonymous or nonsynonymous was excluded from analysis.  Non-parametric methods 
were utilized in the analysis of gene diversity as it was not normally distributed 
(Hollander et al., 2013). The Minitab statistical software package version 13.1 was used 
for all statistical analyses (“Minitab 13.1 Statistical Software,” 2000). 
2.3. Results 
2.3.1 Nucleotide diversity 
In comparisons of nucleotide diversity, πS was greater than πN in CTL epitope 
regions for all four serotypes, significantly greater in 40 of 43 comparisons (Z-tests, two-
tailed, P<0.05 in 3 comparisons, P<0.01 in 5 comparisons, P<0.001 in 32 comparisons), 
except in the NS2B protein of DENV1 as there were no known epitopes found (Tables 
2.1-2.4).  In non-CTL epitope regions of all four serotypes πS was also greater than πN, 
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significantly greater in 42 of 44 comparisons (Z-tests, two-tailed, P<0.05 in 5 
comparisons, P<0.01 in 1 comparisons, P<0.001 in 36 comparisons, Tables 2.1-2.4).   
When comparing the nucleotide diversity of CTL epitope regions and non-CTL 
epitope regions, only the E protein in DENV4 had a significantly higher πN value (Z-test, 
two-tailed, P<0.05) in the CTL epitope regions (Fig. 2.1a).   The NS1 protein of DENV1 , 
NS2B proteins of DENV3 and DENV4, and the NS3 protein in DENV4 all had significantly 
higher πN values in the non-CTL epitope regions (Fig. 2.1b-e).  For synonymous diversity, 
the NS2A and 2K proteins had significantly higher πS values in CTL epitope regions of 
DENV1 while the NS2A protein in DENV4 showed significantly higher πS values in the 
non-CTL epitope regions (Fig. 2.2a-c). 
Comparisons of differences of the ratios of πN to πS between pairs of serotypes 
yielded significant results between the majority of serotype pairs.  Initial testing showed 
significant differences between four of the six comparisons (Sign test, P<0.001) with the 
exception of comparisons between DENV1 and DENV4 and between DENV2 and DENV3.  
Further examination showed significance in five of the six comparisons (Wilcoxon signed 
rank test, P<0.001) excluding only the pair containing both DENV2 and DENV3. 
2.3.2 Gene diversity 
Median synonymous gene diversity was higher in polymorphic sites of known 
CTL epitope and non-CTL epitope regions of all proteins of DENV1 and DENV2 (Fig. A.1-
A.2) except for the CTL epitope regions of NS2B and 2K in DENV1.  This was due to the 
fact that there were no known CTL epitopes found in NS2B and there were not any 
nonsynonymous polymorphic sites found in 2K in DENV1.  The synonymous gene 
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diversity was statistically significant in the majority of the proteins.  Similar results were 
noted for DENV3 (Fig. A.3) except in the case of the non-CTL epitope region of AnchC.  
The median nonsynonymous polymorphic gene diversity was higher in AnchC than its 
corresponding synonymous value however it was not of any significance. 
DENV4 expressed quite different results with the median nonsynonymous 
polymorphic gene diversity exceeding the median synonymous polymorphic gene 
diversity in the CTL epitope regions of AnchC, prM, and E while also showing similar 
patterns in the non-CTL epitope regions of NS3 and 2K, none of which were of any 
significance.  The median gene diversities were equal in the NS1 protein. There were not 
any nonsynonymous polymorphic sites found in the NS2B protein of DENV4.  The 
remainder of the DENV4 proteins had greater median synonymous gene diversity but 
few were statistically significant (Fig. A.4) 
Comparisons of median gene diversity between CTL epitope and non-CTL 
epitope regions were of interest in the AnchC, NS2A, and NS3 proteins of DENV1 (Fig. 
2.3a-c).  Median synonymous gene diversity was significantly higher in CTL epitope 
regions of AnchC and NS2A and in non-CTL epitope regions of NS3.  The median 
nonsynonymous gene diversity in CTL epitope regions of NS1 was notably higher in 
DENV2 (Fig. 2.3d).  DENV3 had higher median nonsynonymous gene diversity in both 
non-CTL epitope regions of AnchC and CTL epitope regions of NS3 (Fig. 2.3e-f).  DENV4 
had higher median synonymous gene diversity in non-CTL epitope regions of AnchC and 
NS2A (Fig. 2.3g-h) while the non-CTL epitope region of NS3 had higher nonsynonymous 
gene diversity (Fig. 2.3i). 
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2.3.3 CTL epitope presence in reconstructed ancestral sequences 
The last common ancestor for each serotype was reconstructed using the 
maximum-parsimony method assuming the NJ tree.  In the initial dataset, 19 known CTL 
epitopes were found in all four DENV serotypes while only 13 (68%) were found across 
all four of the reconstructed ancestral sequences.  163 known CTL epitopes were found 
in the DENV1 dataset and 129 (79%) in the reconstructed DENV1 ancestor.  267 known 
CTL epitopes were found in the DENV2 dataset and 191 (72%) in the reconstructed 
DENV1 ancestor.  196 known CTL epitopes were found in the DENV3 dataset and 151 
(77%) in the reconstructed DENV3 ancestor.  147 known CTL epitopes were found in the 
DENV4 dataset and 129 (88%) in the reconstructed DENV4 ancestor. 
2.4. Discussion 
DENV has been studied significantly in an effort to stem the outbreaks that affect 
millions of individuals globally.  The pursuit for understanding of the virus and how it is 
evolving over time may aide in disease prevention.  An analysis of complete genomes of 
all four DENV serotypes showed several significant patterns in both nucleotide and gene 
diversity.  Evidence of strong past purifying selection was shown by the extremely 
significant pattern of πS > πN both within CTL epitope and non-CTL epitope regions for all 
four serotypes of DENV. 
Similar indications of purifying selection were noted with the patterns in gene 
diversity.  In all proteins of both DENV1 and DENV2, median synonymous gene diversity 
exceeded median nonsynonymous gene diversity in both CTL epitope and non-CTL 
epitope regions.  The majority of the proteins in DENV3 follow the same pattern 
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regarding gene diversity reinforcing that purifying selection is definitely an effective 
force in the evolution of DENV just as it is in many other RNA viruses (Hughes and 
Hughes, 2007).  DENV4 follows somewhat dissimilar patterns when it comes to gene 
diversity compared to the other three serotypes.  Although none of the results for 
proteins or regions of DENV4 were significant, the differences in the patterns suggest 
that this serotype is under different evolutionary pressures. 
Since secondary heterotypic infection tends to be one of the main concerns with 
DENV infection, it was pertinent to test whether serotypes that appeared related 
phylogenetically were indeed similar in their nucleotide diversities in CTL epitope 
regions.  It was found that when comparing ratios of πN to πS for each pair of serotypes 
that there were significant differences (Wilcoxon signed rank test, P<0.001) between 
the median ratios of each pair across the entire genome excluding only the combination 
of DENV2 and DENV3.  This result was not expected based on phylogenies of DENV as 
DENV1 and DENV3 cluster together and would therefore typically share similar ratios if 
selection was occurring comparably in both (Weaver and Vasilakis, 2009).  This further 
signifies that each serotype is not subject to the same mechanisms of evolution in CTL 
epitope regions which aides in explaining the difficulties clearing a secondary 
heterologous infection.   
As escape from immune recognition would be beneficial to the virus itself, one 
would expect to see either some relaxation of purifying selection or positive selection 
showing an increased number of nonsynonymous changes in CTL epitope regions versus 
non-CTL epitope regions as these regions are not readily identified by MHC.  The only 
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protein that showed signs of either relaxation of purifying selection or positive selection 
when examining nucleotide diversity was the E protein in the DENV4 serotype.  The E 
protein also had greater nonsynonymous gene diversity in CTL epitope regions as 
compared to non-CTL epitope regions of DENV4 but this result was not significant.  It is 
possible that positive selection could be acting on the E protein as it is involved directly 
in virus attachment with the host cell and is more prevalent to host cell recognition 
(Hughes and Hughes, 2007; Idrees and Ashfaq, 2012; Iglesias et al., 2014; Piontkivska 
and Hughes, 2006).  If this is indeed the case, it is surprising that only the E protein 
showed significance in DENV4 and not in other serotypes as well. 
Another remarkable result was in the NS3 protein of DENV3.  Median 
nonsynonymous gene diversity in CTL epitope regions of this protein significantly 
exceeded median nonsynonymous gene diversity in non-CTL epitope regions.  This 
anomaly may also be due to positive selection or relaxation of purifying selection.  
Similar results have been noted for the NS3 protein in Hepatitis C, another RNA virus in 
the  Flaviviridae family (Irausquin and Hughes, 2010).  The NS3 protein is vital to the 
replication of the viral RNA and is the pivotal point for replication (Lescar and Lok, 
2014). 
Ancestral reconstructions of the last common ancestor for each serotype 
showed the presence of known CTL epitopes that were found in our dataset.  While 
100% of the CTL epitopes were not conserved in any ancestor, 72% was the minimum 
value for any of the serotypes.  Since the ancestors do contain a large percentage of the 
known CTL epitopes, those that are found in both ancestors and contemporary 
 
19 
sequences may be optimal candidates for vaccine creation.  However, ancestral 
reconstructions may lack escape mutations that the more divergent genomes may have 
now accumulated. 
Analysis of the complete genomes of all four DENV serotypes in this study 
revealed that all serotypes are currently subject to ongoing purifying selection; 
however, there are several noteworthy exceptions within certain proteins of each 
serotype suggesting conflicting evolutionary pressures.  As the mechanism for severity 
of secondary heterotypic infections is still under speculation, perhaps the significance 
conflicting ratios of πN to πS between pairs of serotypes when compared to the viral 
phylogeny can be of some explanation.  Future studies could focus on particular 
proteins rather than the virus as a whole, particularly E and NS3, as E is instrumental in 





Table 2.1. Synonymous (πS) and non-synonymsous (πN) nucleotide diversity (± S.E.) in CTL epitope and non-CTL epitope regions of 
the 11 proteins of DENV1 (Z-tests, two-tailed, rejected the hypotheses that mean πS = mean πN for CTL epitope regions *P<0.05, 
**P<0.01, ***P<0.001; Z-tests, two-tailed, rejected the hypothesis that mean πS = mean πN for non-CTL epitope regions *P<0.05, 
**P<0.01, ***P<0.001). 
 
DENV1   CTL Epitope Region Non-CTL Epitope Region 
Protein n 𝝅S ± S.E. 𝝅N ± S.E. 𝝅S ± S.E. 𝝅N ± S.E. 
AnchC 640 0.132722 ± 0.045187 0.010144 ± 0.005066** 0.048414 ± 0.014175 0.012967 ± 0.004603* 
preM 640 0.333525 ± 0.111373 0.002030 ± 0.001848** 0.155951 ± 0.021165 0.007147 ± 0.002189*** 
E 640 0.151728 ± 0.023791 0.005945 ± 0.002592*** 0.148457 ± 0.010936 0.008248 ± 0.001546*** 
NS1 640 0.153716 ± 0.036706 0.001394 ± 0.000608*** 0.165794 ± 0.015071 0.009230 ± 0.002289*** 
NS2a 640 0.275101 ± 0.049482 0.021878 ± 0.007099*** 0.015913 ± 0.019196 0.013358 ± 0.003003 
NS2b 640 N/A N/A 0.163652 ± 0.024173 0.006573 ± 0.002478*** 
NS3 640 0.125992 ± 0.011680 0.002846 ± 0.001030*** 0.152138 ± 0.012876 0.006220 ± 0.001721*** 
NS4a 640 0.140134 ± 0.038446 0.011301 ± 0.006231*** 0.163706 ± 0.027722 0.007070 ± 0.003767*** 
2K 640 0.198848 ± 0.056279 0.000000 ± 0.000000*** 0.065297 ± 0.037406 0.002092 ± 0.001557 
NS4b 640 0.146876 ± 0.022916 0.002653 ± 0.001422*** 0.133247 ± 0.022160 0.006453 ± 0.002647*** 








Table 2.2. Synonymous (πS) and non-synonymsous (πN) nucleotide diversity (± S.E.) in CTL epitope and non-CTL epitope regions of 
the 11 proteins of DENV2 (Z-tests, two-tailed, rejected the hypotheses that mean πS = mean πN for CTL epitope regions *P<0.05, 
**P<0.01, ***P<0.001; Z-tests, two-tailed, rejected the hypothesis that mean πS = mean πN for non-CTL epitope regions *P<0.05, 
**P<0.01, ***P<0.001). 
 
DENV2  CTL Epitope Region Non-CTL Epitope Region 
Protein n 𝝅S ± S.E. 𝝅N ± S.E. 𝝅S ± S.E. 𝝅N ± S.E. 
AnchC 598 0.156835 ± 0.038395 0.009034 ± 0.005002*** 0.140824 ± 0.039421 0.024135 ± 0.009761** 
preM 598 0.139154 ± 0.039400 0.013998 ± 0.006793** 0.228475 ± 0.034368 0.009684 ± 0.003204*** 
E 598 0.203800 ± 0.020994 0.009471 ± 0.002882*** 0.210192 ± 0.017839 0.009921 ± 0.002218*** 
NS1 598 0.274804 ± 0.043861 0.016930 ± 0.004899*** 0.204652 ± 0.018894 0.009653 ± 0.002289*** 
NS2a 598 0.254570 ± 0.053224 0.031210 ± 0.010899*** 0.255409 ± 0.026457 0.014861 ± 0.003722*** 
NS2b 598 0.259382 ± 0.042397 0.012649 ± 0.005820*** 0.178467 ± 0.038467 0.005037 ± 0.002661*** 
NS3 598 0.220837 ± 0.015193 0.006876 ± 0.001722*** 0.220531 ± 0.022103 0.010276 ± 0.002799*** 
NS4a 598 0.185536 ± 0.029878 0.011192 ± 0.005276*** 0.268489 ± 0.048939 0.009823 ± 0.005002*** 
2K 598 0.194842 ± 0.050233 0.000114 ± 0.000137*** 0.093340 ± 0.037112 0.002399 ± 0.001539* 
NS4b 598 0.270100 ± 0.030465 0.008696 ± 0.002939*** 0.220691 ± 0.033157 0.009601 ± 0.003803*** 






Table 2.3. Synonymous (πS) and non-synonymsous (πN) nucleotide diversity (± S.E.) in CTL epitope and non-CTL epitope regions of 
the 11 proteins of DENV3 (Z-tests, two-tailed, rejected the hypotheses that mean πS = mean πN for CTL epitope regions *P<0.05, 
**P<0.01, ***P<0.001; Z-tests, two-tailed, rejected the hypothesis that mean πS = mean πN for non-CTL epitope regions *P<0.05, 
**P<0.01, ***P<0.001). 
 
DENV3  CTL Epitope Region Non-CTL Epitope Region 
Protein n 𝝅S ± S.E. 𝝅N ± S.E. 𝝅S ± S.E. 𝝅N ± S.E. 
AnchC 341 0.084428 ± 0.024962 0.012673 ± 0.006543** 0.054009 ± 0.017382 0.008089 ± 0.004138* 
preM 341 0.115803 ± 0.045164 0.001566 ± 0.001232* 0.120089 ± 0.017533 0.005351 ± 0.002197*** 
E 341 0.173150 ± 0.040467 0.010361 ± 0.005097*** 0.154298 ± 0.012253 0.007664 ± 0.002027*** 
NS1 341 0.142580 ± 0.026917 0.010503 ± 0.004659*** 0.135931 ± 0.016604 0.005409 ± 0.001670*** 
NS2a 341 0.202068 ± 0.041102 0.012741 ± 0.006977*** 0.162412 ± 0.023427 0.009603 ± 0.002371*** 
NS2b 341 0.153591 ± 0.065513 0.000502 ± 0.000472* 0.132889 ± 0.022444 0.002714 ± 0.000995*** 
NS3 341 0.134788 ± 0.013904 0.003846 ± 0.001227*** 0.161881 ± 0.015291 0.003094 ± 0.001268*** 
NS4a 341 0.210068 ± 0.056317 0.015619 ± 0.010262*** 0.140364 ± 0.026306 0.009322 ± 0.003781*** 
2K 341 0.108676 ± 0.065087 0.000000 ± 0.000000 0.216785 ± 0.078614 0.022914 ± 0.020093* 
NS4b 341 0.138774 ± 0.022417 0.002753 ± 0.001854*** 0.158675 ± 0.024709 0.002266 ± 0.001384*** 








Table 2.4. Synonymous (πS) and non-synonymsous (πN) nucleotide diversity (± S.E.) in CTL epitope and non-CTL epitope regions of 
the 11 proteins of DENV4 (Z-tests, two-tailed, rejected the hypotheses that mean πS = mean πN for CTL epitope regions *P<0.05, 
**P<0.01, ***P<0.001; Z-tests, two-tailed, rejected the hypothesis that mean πS = mean πN for non-CTL epitope regions *P<0.05, 
**P<0.01, ***P<0.001). 
DENV4  CTL Epitope Region Non-CTL Epitope Region 
Protein n 𝝅S ± S.E. 𝝅N ± S.E. 𝝅S ± S.E. 𝝅N ± S.E. 
AnchC 36 0.115883 ± 0.027116 0.020954 ± 0.012113** 0.073152 ± 0.015764 0.003404 ± 0.001473*** 
preM 36 0.169872 ± 0.040193 0.017278 ± 0.013210*** 0.152543 ± 0.017262 0.005526 ± 0.001513*** 
E 36 0.162430 ± 0.027186 0.017320 ± 0.005083*** 0.159463 ± 0.012028 0.006042 ± 0.001199*** 
NS1 36 0.200849 ± 0.049205 0.017177 ± 0.006232*** 0.140621 ± 0.011346 0.011010 ± 0.002164*** 
NS2a 36 0.081079 ± 0.043610 0.045311 ± 0.027673 0.178837 ± 0.018938 0.019418 ± 0.004297*** 
NS2b 36 0.114396 ± 0.053882 0.000000 ± 0.000000* 0.153874 ± 0.021494 0.004968 ± 0.001848*** 
NS3 36 0.147172 ± 0.014668 0.002110 ± 0.000779*** 0.162613 ± 0.012034 0.005374 ± 0.001312*** 
NS4a 36 0.203086 ± 0.038004 0.007198 ± 0.003811*** 0.150597 ± 0.023333 0.004025 ± 0.002246*** 
2K 36 0.016857 ± 0.044667 0.000074 ± 0.005816 0.180962 ± 0.074187 0.016975 ± 0.012043* 
NS4b 36 0.140868 ± 0.018186 0.004717 ± 0.001763*** 0.185194 ± 0.023413 0.002268 ± 0.000771*** 
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Figure 2.1.  Average nucleotide diversity at nonsynonymous polymorphic sites (πN) in regions of CTL epitopes and non-CTL epitopes 
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Figure 2.2.  Average nucleotide diversity at synonymous polymorphic sites (πS) in regions of CTL epitopes and non-CTL epitopes in a) 
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Figure 2.3.  Median gene diversity at synonymous and nonsynonymous polymorphic sites in CTL epitope (Ep) and non-CTL epitope 
(NonEp) regions of a) Anch C of DENV1 b) NS2A of DENV1 c) NS3 of DENV1 d) NS1 of DENV2 e) AnchC of DENV3 f) NS3 of DENV3 g) 





COMPARISON OF THREE EPITOPE PREDICTION SOFTWARE PROGRAMS UTILIZING A DENGUE 
VIRUS DATASET2 
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Vaccines are incredibly important in disease prevention saving millions of lives 
per year.  As there are always new and emerging pathogenic bacteria and viruses as well 
as currently existing ones for which we have not yet successfully engineered a vaccine, 
new methods of vaccine development are invented.  The advent of the genomic era led 
to one such modern approach that deals with the creation of subunit vaccines by mining 
genomes to predict immune response epitopes. 
The Dengue virus (DENV) is a single-stranded RNA virus that has become quite an 
issue with the immune system.  There are four serotypes of DENV (DENV1-4) and while 
infection with a single serotype elicits the normal adaptive immune response, secondary 
infection by a heterologous serotype any time post primary infection tends to produce a 
much more severe reaction and may even lead to death (Rodriguez-Roche and Gould, 
2013; World Health Organization, 2012a).  Due to this severe reaction coupled with the 
issue that the mechanisms behind secondary infection are currently speculated but 
unknown, vaccine development for DENV has become a high priority.  In a previous 
study analysis of both a large dataset of DENV genomes and known epitopes was used 
in speculating evolutionary pressures additionally this data can now be utilized in testing 
several epitope prediction programs. 
The major histocompatibility complex (MHC) of vertebrates (termed human 
leukocyte antigen (HLA) in humans) is a cluster of genes that are integral in 
identification of foreign pathogens (Hughes and Yeager, 1998).  Molecules from class I 
MHC are present in all nucleated cells.  When cells are infected, the MHC encodes for 
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various glycoproteins known as epitopes that are presented outside the cell (Andersen 
et al., 2006; Hughes and Yeager, 1998).  Cytotoxic T cells (CTL) have specialized T cell 
receptors (TCR) that are able to identify these epitopes and trigger T cell proliferation, 
differentiation of these T cells into both effector and memory T cells as well as the 
eradication of the infected cell (Andersen et al., 2006; Hughes and Yeager, 1998).  
Generation of these differentiated T cells by using subunit vaccines of the specific 
protein epitopes known to generate immune response has already been used 
successfully in combating hepatitis B since 1986 and has the potential to aide in 
prevention of other diseases (Hilleman, 2000).  
Prediction of these CTL epitopes has become an increasingly expanding field.  
These in silico methods are particularly important in speedily narrowing the search for 
possible immunologically responsive proteins before conducting extensive, costly wet 
lab experiments (Yang and Yu, 2009).  Prediction methods vary between programs as 
views on which method is best differ between researchers.  This study compared the 
efficacy of three epitope prediction software programs to identify known DENV 
epitopes.  Each program used different prediction methods in determining overall 
prediction scores. 
3.2. Methods 
3.2.1 Known epitopes and sequences utilized in comparisons 
Previously, 525 known human CTL epitopes presented by MHC class I were 
obtained from the Immune Epitope Database and Analysis Resource (IEDB) available at 
http://www.iedb.org/ (Kim et al., 2012; Vita et al., 2010).  Also, 1615 complete genome 
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sequences of DENV were obtained from the Dengue Virus Database available at 
http://www.denguedb.org/index.asp (Viral Bioinformatics Resource Center, 2009), 640 
belonging to DENV1, 598 to DENV2, 341 to DENV3 and 36 to DENV4.  These sequences 
were placed into the correct reading frame and aligned at the amino acid level followed 
by superimposition back onto their nucleotide frames as noted in Chapter 2.  Each 
serotype was inspected to find the complete genome or genomes within that serotype 
that contained the most epitope coverage (Table B.1).  Two serotypes had several 
sequences with the same amount of coverage therefore all of these were used in 
analysis. 
3.2.2 Epitope prediction programs 
Several epitope prediction applications were selected based on various traits 
including that they were all accessible as freeware.  NetCTL was among these programs 
as it has been shown to be more effective in the prediction of MHC class I CTL epitopes 
for HIV than several other alternative programs including EpiJen, MAPPP, MHC-
pathway, and WAPP (Larsen et al., 2007).  Initially NetCTL was administered on a LINUX 
platform but the results were the same when utilizing its web-based terminal which had 
a more user-friendly interface.  Complete polyprotein sequences of those individual 
genomes containing the most epitope coverage were processed by the program.  
NetCTL ranks predictions utilizing several scores, one of which is the combination of all 
the more specific sub scores.  The top 25% of results with the highest combination 
scores were recorded for comparison. 
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The second program chosen was SVMHC as it also used to predict MHC Class I 
CTL epitopes (Dönnes and Kohlbacher, 2006).  The program was also ranked as having 
91-100% accuracy in the Receiver Operating Characteristic curve value of Yang and Yu’s 
review of several T cell epitope prediction methods (Yang and Yu, 2009).  Two sets of 
results were obtained from SVMHC as it utilizes two separate databases, the SYFPEITHI 
database for MHC ligands (Rammensee et al., 1999) and the MHCPEP database of MHC 
class I and II binding peptides (Brusic et al., 1994), when determining prediction scores.  
The same complete polyprotein sequences of the genomes with the most known 
epitope coverage were processed using SVMHC’s web-based interface.  The MHCPEP 
and SYFPEITHI results were combined for analyses and the top 25% saved for 
comparison. 
The IEDB has its own MHC Class I T cell epitope prediction software and was 
utilized as the final program as it is also the site where the known CTL epitopes being 
used for comparison were obtained.  IEDB’s tool incorporates several prediction 
methods including artificial neural networks (Lundegaard et al., 2008; Nielsen et al., 
2003), stabilized matrix methods (Peters and Sette, 2005), and positional scanning of 
combined peptide libraries (Sidney et al., 2008).  The same polyprotein sequences were 
employed again and only the top 25% of the results retained.  It is of note that IEDB’s 
program does not allow input sequences to possess gaps therefore gaps were removed 





3.2.3 Sensitivity measure of performance 
 Sensitivity of each program was determined by computing true positive predictions 
(the number of correctly predicted epitopes) and dividing this by actual positives 
obtained from the IEDB.  This was performed amongst both the top 25% of results as 
well as the top 5% for each of the three programs.  Not all available MHC supertypes 
were utilized in computing sensitivity.  Seven supertypes were common among all three 
programs (Table 3.1) therefore comparison was restricted to results from the seven 
common supertypes in order to prevent bias. 
3.2.4 RANK measure 
 Similarly to a measure utilized in NetCTL’s HIV dataset comparison (Larsen et al., 
2007), each true positive epitope identified by a pair of programs was observed 
individually.  Whichever program of the pair gave the true positive epitope the higher 
score (standardized by number of scores generated per each program in either top 25% 
or top 5%), was counted as having a better predictive performance in each case.  These 
counts were utilized as a RANK measure to determine overall predictive performance 
and were compared using a binomial distribution assuming that each software had a 
50% chance of having the higher RANK measure. 
3.3. Results 
3.2.1 Sensitivity measures 
Performance comparison of sensitivity of the three programs showed that IEDB 
had much higher percentages in the top 25% of results followed by NetCTL then SVMHC 
(Table 3.2a, Fig. 3.1a).  When examining the top 5%, NetCTL slightly outperformed IEDB 
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in the datasets containing DENV1, DENV2 and DENV4 although the results were within 
4% for all three serotypes (Table 3.2b Fig. 3.1b).  IEDB and NetCTL had almost identical 
sensitivity (30.10% and 29.59% respectively) for DENV3 (Table 3.2, Fig. 3.1b).  SVMHC 
again had drastically lower sensitivity (Table 3.2b, Fig. 3.1b). 
3.2.2 RANK measures 
Comparisons of RANK scoring for the top 25% of predictions were highly 
significant across all four serotypes as well as all four combined in favor of IEDB when 
comparing IEDB to SVMHC and in favor of NetCTL when comparing NetCTL to SVMHC 
(P<0.001 in all cases, Table B.2a, Fig. 3.2a-e).  When comparing IEDB and NetCTL, results 
were significantly in favor of IEDB in DENV1, DENV3 (P<0.05 in both cases, Fig. 3.2a, Fig. 
3.2c) and in all serotypes combined (P<0.01, Fig. 3.2e).  RANK measure results were 
similar for the top 5% of epitope prediction results (Table B.2b).  IEDB versus SVMHC 
had significance in favor of IEDB for DENV1 (P<0.05, Fig. 3.3a), DENV2, DENV4 (P<0.01 in 
both cases, Fig. 3.3b, Fig. 3.3d) and in all serotypes combined (P<0.001, Fig 3.3e).  The 
comparisons of NetCTL and SVMHC only significantly favored NetCTL in DENV3 (P<0.01, 
Fig. 3.3c) and the combination of all serotypes (P<0.001, Fig. 3.3e).  RANK measures of 
IEDB and NetCTL showed that IEDB was favored significantly in DENV3 (P<0.05, Fig. 3.3c) 
and in all serotypes combine (P<0.01, Fig. 3.3e). 
3.4. Discussion 
Epitope prediction software programs are becoming more sophisticated with 
advances in technology (Delany et al., 2014; Gilbert, 2011; He et al., 2010).  The 
expansion of our understanding immunological response is aiding the efficacy of these 
 
34 
programs and their ability to help in the prevention of future illness.  Due to the severity 
of a secondary heterotypic DENV infection causing extreme reactions in humans, 
vaccine creation for the virus has been extremely difficult which makes it a prime 
candidate for vaccine informatics in order to unearthing potential epitopes that may 
exist amongst all four DENV serotypes. 
Of the three programs (IEDB, NetCTL, and SVMHC) compared utilizing complete 
genomes of all four serotypes of DENV as well as known epitopes obtained from the 
IEDB, there were clear differences in both sensitivity and RANK measures for each 
program.  Percentages of sensitivity when comparing the top 25% of results from each 
program showed IEDB to have the highest performance.  However, if only the top 5% of 
prediction results are compared, IEDB and NetCTL both have similar sensitivity 
percentages.  Both IEDB and NetCTL are clearly capable of predicting true epitopes at 
least 20% of the time within the top 5% of their total results. 
The IEDB program produces an exorbitant number of results in comparison to 
both NetCTL and SVMHC.  In order to control for the discrepancy in the number of 
results as well as for identification of different true epitopes, the RANK measure was 
employed to determine if the higher sensitivity percentages were wholly due to having a 
larger number of results.  IEDB outperformed both NetCTL and SVMHC in the top 25% 
and 5% of prediction results when comparing RANK measures although NetCTL also 
performed well.  Differences between IEDB and NetCTL results were not always 
significant.  The IEDB may have had superior performance as its CTL epitope database 
was the one utilized in the search for the known DENV epitopes used in this study. 
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SVMHC had the lowest performance across all sensitivity percentages and RANK 
measures at both the 5% and 25% mark.  This program was initially chosen due to its 
high accuracy which also takes specificity of prediction and false positives into account.  
Specificity is defined by dividing the number of true negative epitopes (proteins that are 
correctly predicted as non-epitopes) by the actual number of non-epitopes in the 
dataset.  This study solely examined the ability to predict true epitopes and was not 
concerned with either false positive results or predicted non-epitope proteins.  SVMHC’s 
results were only available at three peptide lengths (octamer, nonamer and decamer) 
while IEDB and NetCTL could both predict larger epitopes.  Either of these facts may 
explain SVMHC’s poor performance. 
As subunit vaccines are typically more efficient to manufacture than other types 
of vaccines as well as having little to no adverse effects, the ability to precisely predict 
which epitopes will cause the most significant immune response is critical to the future 
of vaccine development.  Therefore the expanding field of software programs that 
predict epitopes will be vital to the development of new subunit vaccines.  Both IEDB 
and NetCTL are such programs that employ several immunological methods in concert 
for their predictions.  Both outperformed SVMHC which only utilizes support vector 
machines.  This study suggests that programs combining several methods, both 
immunologically and computationally based are the most successful in terms of both 




Table 3.1.  Representative shared HLA supertype alleles for each of the three software 
programs compared.  Each program had many other alleles available however these 
were not shared amongst all three and therefore not used in comparison. 
 

































Table 3.2a.  Sensitivity percentages at top 25% of prediction results for all four DENV 
serotypes individually as well as all serotypes combined. 
 
Program DENV1 DENV2 DENV3 DENV4 All DENV 
IEDB 71.17 59.18 68.88 74.83 98.86 
NetCTL 39.26 31.46 38.78 41.50 54.29 
SVMHC 15.34 8.61 13.27 17.01 18.86 
 
Table 3.2b.  Sensitivity percentages at top 5% of prediction results for all four DENV 
serotypes individually as well as all serotypes combined. 
 
Program DENV1 DENV2 DENV3 DENV4 All DENV 
IEDB 27.61 20.97 30.10 28.57 38.48 
NetCTL 31.29 23.97 29.59 31.29 41.71 









Figure 3.1.  Sensitivity percentages for all four serotypes individually and combined in 
comparisons of IEDB, NetCTL, and SVMHC epitope prediction software at a) top 5% of 
predicted results and b) top 25% of predicted results. 
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A)            B) 
   
C)            D) 
   
E)             
 
Figure 3.2.  Rank measures of top 25% of predictions for comparisons of counts of 
epitope rank by pairs of epitope prediction programs for datasets of a) DENV1 b) DENV2 
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Figure 3.3.  Rank measures of top 5% of predictions for comparisons of counts of 
epitope rank by pairs of epitope prediction programs for datasets of a) DENV1 b) DENV2 






The results of our first study support that there are significant differences in both 
nucleotide polymorphism and gene diversity between DENV serotypes facilitating 
understanding of severe immune response to a secondary heterologous infection.  This 
data suggests conflicting evolutionary pressures on each serotype including an 
abundance of purifying selection as well as positive selection coupled with relaxation of 
purifying selection in attempts to escape immune system recognition. 
Not only are there significant differences between the serotypes but also 
between CTL epitope and non-CTL epitope regions of the E protein of DENV4, NS1 
protein of DENV2, and NS3 protein of DENV3.  These results indicate that the conflicting 
evolutionary pressures exist within each serotype as well, particularly affecting proteins 
that are of interest in class I MHC identification but interestingly enough not across all 
four serotypes equally. 
Results comparing the efficacy of epitope prediction applications demonstrated 
that programs incorporating several methods including algorithms, neural networks, 
matrices and peptide library searches were more capable of assigning higher scores to 
known DENV epitopes.  The two multiple method programs, IEDB and NetCTL, 
significantly outperformed a single method program, SVMHC, in both RANK measures 
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and sensitivity percentages.  As epitope prediction software programs are becoming 
more readily used in assistance with subunit vaccine creation, the efficacy of each 
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APPENDIX A – CHAPTER 2 SUPPLEMENTARY INFORMATION 
Table A.1.  GenBank accession numbers for complete genome sequences retrieved from 
the Dengue Virus Database. 
 
Accession  Serotype   Accession Serotype 
1 AB178040 1  809 EU687214 2 
2 EU081229 1  810 EU687215 2 
3 EU081230 1  811 EU687216 2 
4 EU081231 1  812 EU726770 2 
5 EU081232 1  813 EU687217 2 
6 EU081233 1  814 EU781135 2 
7 EU081234 1  815 EU687220 2 
8 EU081235 1  816 EU726775 2 
9 EU081236 1  817 EU726767 2 
10 EU081237 1  818 EU687222 2 
11 EU081238 1  819 EU687223 2 
12 EU081239 1  820 EU687224 2 
13 EU081240 1  821 EU687225 2 
14 EU081241 1  822 EU687227 2 
15 EU081242 1  823 EU687228 2 
16 EU081243 1  824 EU687229 2 
17 EU081244 1  825 EU687230 2 
18 EU081245 1  826 EU687231 2 
19 EU081246 1  827 EU687232 2 
20 EU081247 1  828 EU687199 2 
21 EU081248 1  829 EU687235 2 
22 EU081249 1  830 EU687236 2 
23 EU081250 1  831 EU687237 2 
24 EU081251 1  832 EU687238 2 
25 EU081252 1  833 EU687240 2 
26 EU081253 1  834 EU687241 2 
27 EU081254 1  835 EU687242 2 
28 EU081255 1  836 EU687243 2 
29 EU081256 1  837 EU687244 2 
30 EU081257 1  838 EU687245 2 
31 EU081258 1  839 EU687246 2 
32 EU081259 1  840 EU660413 2 
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33 EU081260 1  841 EU660414 2 
34 EU081261 1  842 EU687248 2 
35 EU081262 1  843 EU660415 2 
36 EU081263 1  844 EU660416 2 
37 EU081264 1  845 EU726776 2 
38 EU081265 1  846 EU660417 2 
39 EU081266 1  847 EU677137 2 
40 EU081267 1  848 EU677138 2 
41 EU081268 1  849 EU677148 2 
42 EU081269 1  850 EU677149 2 
43 EU081270 1  851 EU687250 2 
44 EU081271 1  852 FJ024473 2 
45 EU081272 1  853 FJ024474 2 
46 EU081273 1  854 FJ024475 2 
47 EU081274 1  855 FJ182012 2 
48 EU081275 1  856 FJ390389 2 
49 EU081276 1  857 EU854293 2 
50 EU081277 1  858 EU854294 2 
51 EU081278 1  859 FJ024477 2 
52 EU081279 1  860 FJ410288 2 
53 EU081226 1  861 FJ024452 2 
54 EU081227 1  862 FJ205877 2 
55 EU081228 1  863 FJ024454 2 
56 EU081280 1  864 FJ390384 2 
57 EU081281 1  865 FJ205878 2 
58 AF180817 1  866 FJ205879 2 
59 AF180818 1  867 FJ390385 2 
60 AF514883 1  868 FJ024458 2 
61 AF514878 1  869 FJ205880 2 
62 AY206457 1  870 FJ390387 2 
63 AF514885 1  871 FJ024461 2 
64 AF514889 1  872 FJ373299 2 
65 AF514876 1  873 FJ205885 2 
66 EF025110 1  874 FJ410193 2 
67 AB189120 1  875 FJ410195 2 
68 AB189121 1  876 FJ432726 2 
69 AB074761 1  877 FJ562098 2 
70 AF298807 1  878 FJ410200 2 
71 AY277665 1  879 FJ410202 2 
72 AY277666 1  880 FJ410208 2 
73 AY277664 1  881 FJ461305 2 
74 EU482615 1  882 FJ410215 2 
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75 EU482616 1  883 FJ461309 2 
76 EU482617 1  884 FJ461311 2 
77 EU482618 1  885 FJ410217 2 
78 EU482619 1  886 FJ410219 2 
79 EU482609 1  887 FJ461314 2 
80 EU482610 1  888 FJ410221 2 
81 EU482611 1  889 FJ547064 2 
82 EU482567 1  890 FJ410223 2 
83 EU660396 1  891 FJ410224 2 
84 EU660390 1  892 FJ461321 2 
85 EU660391 1  893 FJ410228 2 
86 EU660392 1  894 FJ410233 2 
87 EU660393 1  895 FJ410237 2 
88 EU660394 1  896 FJ410241 2 
89 EU660401 1  897 FJ410259 2 
90 FJ373305 1  898 FJ547067 2 
91 EU660402 1  899 FJ639697 2 
92 EU660403 1  900 FJ639698 2 
93 EU660397 1  901 FJ639699 2 
94 EU687247 1  902 FJ639700 2 
95 EU660395 1  903 FJ639701 2 
96 EU660412 1  904 FJ639702 2 
97 EU660418 1  905 FJ639703 2 
98 EU677150 1  906 FJ639704 2 
99 EU677151 1  907 FJ639705 2 
100 EU677152 1  908 FJ639706 2 
101 EU677153 1  909 FJ639707 2 
102 EU677154 1  910 FJ639708 2 
103 EU677155 1  911 FJ639709 2 
104 EU677156 1  912 FJ639710 2 
105 EU677157 1  913 FJ639711 2 
106 EU726777 1  914 FJ639717 2 
107 EU677158 1  915 FJ639718 2 
108 EU677159 1  916 FJ639828 2 
109 EU677160 1  917 FJ639829 2 
110 EU677161 1  918 FJ639830 2 
111 EU677162 1  919 FJ639831 2 
112 EU677163 1  920 FJ639832 2 
113 EU677164 1  921 FJ639732 2 
114 EU677165 1  922 FJ639733 2 
115 EU677139 1  923 FJ639734 2 
116 EU677140 1  924 FJ639783 2 
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117 EU677166 1  925 FJ639788 2 
118 EU677167 1  926 FJ639809 2 
119 EU677168 1  927 FJ639822 2 
120 EU677169 1  928 FJ639834 2 
121 EU677170 1  929 FJ639835 2 
122 EU726778 1  930 FJ639836 2 
123 EU677171 1  931 FJ639837 2 
124 EU677172 1  932 EU482748 2 
125 EU677173 1  933 EU482749 2 
126 EU677174 1  934 EU482750 2 
127 EU726779 1  935 EU482751 2 
128 EU660419 1  936 EU482752 2 
129 EU677175 1  937 EU482753 2 
130 EU677176 1  938 EU482770 2 
131 EU726780 1  939 FJ226066 2 
132 EU726781 1  940 EU482680 2 
133 EU677177 1  941 EU482754 2 
134 EU726782 1  942 EU482755 2 
135 EU677178 1  943 FJ478455 2 
136 EU687251 1  944 EU482756 2 
137 FJ024425 1  945 EU482757 2 
138 FJ024426 1  946 EU482758 2 
139 FJ024427 1  947 EU482759 2 
140 FJ024428 1  948 EU482681 2 
141 FJ024429 1  949 EU482761 2 
142 FJ024430 1  950 EU482762 2 
143 FJ024431 1  951 EU482763 2 
144 FJ024432 1  952 EU482771 2 
145 FJ024433 1  953 EU482682 2 
146 FJ024434 1  954 EU482444 2 
147 FJ024435 1  955 EU482772 2 
148 FJ024436 1  956 EU482773 2 
149 FJ024437 1  957 EU482683 2 
150 FJ024472 1  958 EU482684 2 
151 FJ024438 1  959 EU482685 2 
152 FJ024439 1  960 EU482686 2 
153 FJ024440 1  961 EU482687 2 
154 FJ024441 1  962 EU482688 2 
155 FJ024442 1  963 EU482689 2 
156 FJ024443 1  964 EU482690 2 
157 FJ024444 1  965 EU482691 2 
158 FJ373296 1  966 EU482692 2 
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159 FJ182018 1  967 EU482693 2 
160 FJ410287 1  968 EU482694 2 
161 FJ182019 1  969 EU529706 2 
162 FJ432719 1  970 EU482719 2 
163 FJ182020 1  971 EU482720 2 
164 FJ024445 1  972 EU482721 2 
165 FJ182021 1  973 EU482722 2 
166 FJ182022 1  974 EU482723 2 
167 FJ024446 1  975 EU482724 2 
168 FJ182023 1  976 EU482725 2 
169 FJ024447 1  977 EU482726 2 
170 FJ182024 1  978 EU482727 2 
171 FJ182025 1  979 EU482728 2 
172 FJ373297 1  980 EU482729 2 
173 FJ024448 1  981 EU482730 2 
174 FJ182026 1  982 EU482731 2 
175 FJ373298 1  983 EU596483 2 
176 FJ182027 1  984 EU482597 2 
177 FJ390381 1  985 EU482598 2 
178 FJ182028 1  986 EU482603 2 
179 FJ024449 1  987 EU482599 2 
180 FJ390382 1  988 EU482632 2 
181 FJ182003 1  989 EU482600 2 
182 FJ182029 1  990 EU482633 2 
183 FJ390383 1  991 EU482634 2 
184 FJ024450 1  992 EU482635 2 
185 FJ182030 1  993 EU482636 2 
186 FJ182031 1  994 EU482637 2 
187 FJ182032 1  995 EU596484 2 
188 FJ024451 1  996 EU482638 2 
189 FJ182033 1  997 EU482601 2 
190 FJ182034 1  998 EU482631 2 
191 FJ182035 1  999 EU482602 2 
192 FJ182036 1  1000 EU482639 2 
193 FJ410289 1  1001 EU482732 2 
194 FJ024453 1  1002 EU482733 2 
195 FJ205876 1  1003 EU482734 2 
196 FJ024455 1  1004 EU482735 2 
197 FJ024456 1  1005 EU482736 2 
198 FJ024457 1  1006 EU482737 2 
199 FJ390386 1  1007 EU482738 2 
200 FJ024459 1  1008 EU482739 2 
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201 FJ205881 1  1009 EU482740 2 
202 FJ024460 1  1010 EU482741 2 
203 FJ205882 1  1011 EU482742 2 
204 FJ205883 1  1012 EU482743 2 
205 FJ205884 1  1013 EU482744 2 
206 FJ024462 1  1014 EU482745 2 
207 FJ024463 1  1015 EU482746 2 
208 FJ390388 1  1016 EU482747 2 
209 FJ024464 1  1017 EU482764 2 
210 FJ390374 1  1018 EU482765 2 
211 FJ390378 1  1019 EU482766 2 
212 FJ205872 1  1020 EU482767 2 
213 FJ205873 1  1021 EU482768 2 
214 FJ390379 1  1022 EU482640 2 
215 FJ390380 1  1023 EU482641 2 
216 FJ205874 1  1024 EU482642 2 
217 FJ205875 1  1025 EU482643 2 
218 FJ410191 1  1026 EU482644 2 
219 FJ432723 1  1027 EU482645 2 
220 FJ410192 1  1028 EU482646 2 
221 FJ410194 1  1029 EU482647 2 
222 FJ432725 1  1030 EU482648 2 
223 FJ432727 1  1031 EU482649 2 
224 FJ432729 1  1032 EU482650 2 
225 FJ432730 1  1033 EU482651 2 
226 FJ432732 1  1034 EU482652 2 
227 FJ432733 1  1035 EU482653 2 
228 FJ410196 1  1036 EU482654 2 
229 FJ410197 1  1037 EU482655 2 
230 FJ432734 1  1038 EU482656 2 
231 FJ432735 1  1039 EU482657 2 
232 FJ432736 1  1040 EU482658 2 
233 FJ410198 1  1041 EU482659 2 
234 FJ432737 1  1042 EU482660 2 
235 FJ410199 1  1043 EU482661 2 
236 FJ432738 1  1044 EU482662 2 
237 FJ432739 1  1045 EU482663 2 
238 FJ432740 1  1046 EU482664 2 
239 FJ410201 1  1047 EU482665 2 
240 FJ410203 1  1048 EU482666 2 
241 FJ410204 1  1049 EU482667 2 
242 FJ432742 1  1050 EU482668 2 
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243 FJ410205 1  1051 EU482669 2 
244 FJ410206 1  1052 EU482670 2 
245 FJ410207 1  1053 EU482671 2 
246 FJ432744 1  1054 EU482672 2 
247 FJ547060 1  1055 EU482673 2 
248 FJ432745 1  1056 EU482674 2 
249 FJ410209 1  1057 EU482675 2 
250 FJ410210 1  1058 EU482676 2 
251 FJ432746 1  1059 EU482677 2 
252 FJ410211 1  1060 EU482678 2 
253 FJ432747 1  1061 EU482679 2 
254 FJ432748 1  1062 EU482695 2 
255 FJ432749 1  1063 EU482769 2 
256 FJ461306 1  1064 EU482696 2 
257 FJ410212 1  1065 EU482774 2 
258 FJ461307 1  1066 EU482775 2 
259 FJ410213 1  1067 EU482776 2 
260 FJ461308 1  1068 EU482777 2 
261 FJ410214 1  1069 EU482778 2 
262 FJ461310 1  1070 EU482779 2 
263 FJ410216 1  1071 EU482780 2 
264 FJ562101 1  1072 EU482781 2 
265 FJ461312 1  1073 EU482782 2 
266 FJ461313 1  1074 EU482783 2 
267 FJ547063 1  1075 EU482784 2 
268 FJ410218 1  1076 EU482785 2 
269 FJ461315 1  1077 EU482786 2 
270 FJ461316 1  1078 EU482787 2 
271 FJ461317 1  1079 EU482788 2 
272 FJ410220 1  1080 EU482697 2 
273 FJ410222 1  1081 EU482698 2 
274 FJ461318 1  1082 EU482699 2 
275 FJ461319 1  1083 EU482700 2 
276 FJ410225 1  1084 EU482701 2 
277 FJ410226 1  1085 EU482702 2 
278 FJ410227 1  1086 EU482703 2 
279 FJ547065 1  1087 EU482704 2 
280 FJ410230 1  1088 EU482705 2 
281 FJ410231 1  1089 EU482590 2 
282 FJ461323 1  1090 EU482593 2 
283 FJ461324 1  1091 EU482594 2 
284 FJ461325 1  1092 EU482463 2 
 
57 
285 FJ410232 1  1093 EU482464 2 
286 FJ461327 1  1094 EU482465 2 
287 FJ410234 1  1095 EU482466 2 
288 FJ410235 1  1096 EU482467 2 
289 FJ410236 1  1097 EU482468 2 
290 FJ410238 1  1098 EU482469 2 
291 FJ410239 1  1099 EU482470 2 
292 FJ410240 1  1100 EU482471 2 
293 FJ410242 1  1101 EU482472 2 
294 FJ410243 1  1102 EU482473 2 
295 FJ410244 1  1103 EU482474 2 
296 FJ410245 1  1104 EU482475 2 
297 FJ461330 1  1105 EU482541 2 
298 FJ410246 1  1106 EU482542 2 
299 FJ410247 1  1107 EU482543 2 
300 FJ410248 1  1108 AF489932 2 
301 FJ410249 1  1109 AF100463 2 
302 FJ410250 1  1110 AF100464 2 
303 FJ410251 1  1111 AF100461 2 
304 FJ410252 1  1112 AF100462 2 
305 FJ410253 1  1113 AF119661 2 
306 FJ410254 1  1114 FM210236 2 
307 FJ461331 1  1115 FM210214 2 
308 FJ410255 1  1116 AY702036 2 
309 FJ410256 1  1117 AY702034 2 
310 FJ410257 1  1118 AY702038 2 
311 FJ461332 1  1119 AY702039 2 
312 FJ410258 1  1120 AY702035 2 
313 FJ461333 1  1121 AY702037 2 
314 FJ410260 1  1122 EF105382 2 
315 FJ410261 1  1123 EF105381 2 
316 FJ461335 1  1124 EF105380 2 
317 FJ410262 1  1125 EF105383 2 
318 FJ410263 1  1126 EF105386 2 
319 FJ410264 1  1127 EF105385 2 
320 FJ410265 1  1128 EF457904 2 
321 FJ461336 1  1129 FM210215 2 
322 FJ410266 1  1130 FM210216 2 
323 FJ410267 1  1131 FM210217 2 
324 FJ410268 1  1132 FM210218 2 
325 FJ410269 1  1133 FM210237 2 
326 FJ410270 1  1134 FM210219 2 
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327 FJ410271 1  1135 FM210220 2 
328 FJ410272 1  1136 FM210221 2 
329 FJ410273 1  1137 FM210208 2 
330 FJ410274 1  1138 FM210209 2 
331 FJ410275 1  1139 FM210210 2 
332 FJ410276 1  1140 FM210222 2 
333 FJ410277 1  1141 FM210202 2 
334 FJ410278 1  1142 FM210223 2 
335 FJ410279 1  1143 FM210203 2 
336 FJ410280 1  1144 FM210211 2 
337 FJ410281 1  1145 AB122020 2 
338 FJ410282 1  1146 AB122021 2 
339 FJ410283 1  1147 AB122022 2 
340 FJ410284 1  1148 EU179858 2 
341 FJ410285 1  1149 EU179859 2 
342 FJ410286 1  1150 EU179857 2 
343 FJ461339 1  1151 AF276619 2 
344 FJ461341 1  1152 AF359579 2 
345 FJ639669 1  1153 AY702040 2 
346 FJ639670 1  1154 EU056811 2 
347 FJ639671 1  1155 AF100467 2 
348 FJ639672 1  1156 AF100468 2 
349 FJ639673 1  1157 M20558 2 
350 FJ639674 1  1158 AF100459 2 
351 FJ639675 1  1159 AF100460 2 
352 FJ639676 1  1160 AF100466 2 
353 FJ639677 1  1161 AF208496 2 
354 FJ639678 1  1162 FM210231 2 
355 FJ639679 1  1163 FM210239 2 
356 FJ639680 1  1164 FM210232 2 
357 FJ639681 1  1165 FM210233 2 
358 FJ639682 1  1166 FM210240 2 
359 FJ639683 1  1167 FM210241 2 
360 FJ639684 1  1168 FM210242 2 
361 FJ639685 1  1169 FM210243 2 
362 FJ639686 1  1170 FM210244 2 
363 FJ639687 1  1171 FM210234 2 
364 FJ639688 1  1172 FM210213 2 
365 FJ639689 1  1173 FM210235 2 
366 FJ639690 1  1174 FM210245 2 
367 FJ639691 1  1175 FM210205 2 
368 FJ639692 1  1176 FM210206 2 
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369 FJ639693 1  1177 FM210246 2 
370 FJ639694 1  1178 FM210207 2 
371 FJ639695 1  1179 FM210238 2 
372 FJ639696 1  1180 FM210224 2 
373 FJ410173 1  1181 FM210225 2 
374 FJ410174 1  1182 FM210226 2 
375 FJ410175 1  1183 FM210227 2 
376 FJ562105 1  1184 FM210212 2 
377 FJ562106 1  1185 FM210204 2 
378 FJ410179 1  1186 FM210228 2 
379 FJ410180 1  1187 FM210229 2 
380 FJ410181 1  1188 FM210230 2 
381 FJ547086 1  1189 M29095 2 
382 FJ410182 1  1190 AF038403 2 
383 FJ410183 1  1191 AF038402 2 
384 FJ410184 1  1192 EF105379 2 
385 FJ410185 1  1193 DL138662 2 
386 FJ547087 1  1194 CS477302 2 
387 FJ410186 1  1195 CS479165 2 
388 FJ410187 1  1196 CS479167 2 
389 FJ478457 1  1197 FB730117 2 
390 FJ410188 1  1198 GM059692 2 
391 FJ410189 1  1199 U87412 2 
392 FJ478458 1  1200 AJ968413 2 
393 FJ410190 1  1201 EF105378 2 
394 FJ639735 1  1202 M19197 2 
395 FJ639740 1  1203 AY858036 2 
396 FJ639741 1  1204 DQ181799 2 
397 FJ639743 1  1205 DQ181802 2 
398 FJ639794 1  1206 DQ181806 2 
399 FJ639796 1  1207 DQ181798 2 
400 FJ639797 1  1208 DQ181797 2 
401 FJ639802 1  1209 DQ181805 2 
402 FJ639806 1  1210 DQ181800 2 
403 FJ639808 1  1211 DQ181801 2 
404 FJ639811 1  1212 DQ181803 2 
405 FJ639812 1  1213 DQ181804 2 
406 FJ639813 1  1214 AF022434 2 
407 FJ639814 1  1215 AF022437 2 
408 FJ639815 1  1216 AF022438 2 
409 FJ639818 1  1217 AF022439 2 
410 FJ639819 1  1218 AF022440 2 
 
60 
411 FJ639820 1  1219 AF022435 2 
412 FJ639821 1  1220 AF169678 2 
413 FJ639823 1  1221 AF169679 2 
414 FJ639824 1  1222 AF169680 2 
415 FJ547088 1  1223 AF022436 2 
416 FJ547068 1  1224 AF169682 2 
417 FJ562104 1  1225 AF169681 2 
418 FJ432721 1  1226 AF169683 2 
419 FJ024483 1  1227 AF169684 2 
420 FJ024478 1  1228 AF169685 2 
421 EU596504 1  1229 AF169686 2 
422 FJ024481 1  1230 AF169687 2 
423 EU596502 1  1231 AF169688 2 
424 FJ410290 1  1232 AF022441 2 
425 FJ432720 1  1233 AY744147 2 
426 FJ024423 1  1234 AY037116 2 
427 FJ024485 1  1235 AY776328 2 
428 FJ547089 1  1236 AF100465 2 
429 FJ024484 1  1237 EU359009 2 
430 EU596503 1  1238 EF051521 2 
431 FJ024479 1  1239 EU081193 3 
432 FJ182002 1  1240 EU081194 3 
433 FJ024482 1  1241 EU081195 3 
434 EU596501 1  1242 EU081196 3 
435 FJ024480 1  1243 EU081197 3 
436 EU482789 1  1244 EU081198 3 
437 EU482790 1  1245 EU081199 3 
438 EU482791 1  1246 EU081200 3 
439 EU482792 1  1247 EU081201 3 
440 EU482706 1  1248 EU081202 3 
441 EU482707 1  1249 EU081203 3 
442 EU482708 1  1250 EU081204 3 
443 EU482709 1  1251 EU081205 3 
444 EU482710 1  1252 EU081206 3 
445 EU482711 1  1253 EU081207 3 
446 EU482712 1  1254 EU081208 3 
447 EU482713 1  1255 EU081209 3 
448 EU482714 1  1256 EU081210 3 
449 EU482715 1  1257 EU081211 3 
450 EU482716 1  1258 EU081212 3 
451 EU482717 1  1259 EU081213 3 
452 EU482718 1  1260 EU081214 3 
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453 EU249490 1  1261 EU081215 3 
454 EU249491 1  1262 EU081216 3 
455 EU249492 1  1263 EU081217 3 
456 EU249493 1  1264 EU081218 3 
457 EU249494 1  1265 EU081219 3 
458 EU249495 1  1266 EU081220 3 
459 EU482793 1  1267 EU081221 3 
460 EU482794 1  1268 EU081222 3 
461 EU482795 1  1269 EU081223 3 
462 EU482796 1  1270 EU081224 3 
463 EU482797 1  1271 EU081225 3 
464 EU482798 1  1272 EU081182 3 
465 EU482799 1  1273 EU081183 3 
466 EU482800 1  1274 EU081184 3 
467 EU482801 1  1275 EU081185 3 
468 EU482802 1  1276 EU081186 3 
469 EU482803 1  1277 EU081187 3 
470 EU482804 1  1278 EU081188 3 
471 EU482805 1  1279 EU081189 3 
472 EU482806 1  1280 EU081190 3 
473 EU482807 1  1281 EU081191 3 
474 EU482808 1  1282 EU081192 3 
475 EU482809 1  1283 AY099337 3 
476 EU482810 1  1284 NC_001475 3 
477 EU482811 1  1285 AF317645 3 
478 EU482812 1  1286 AY858038 3 
479 EU482813 1  1287 DQ675519 3 
480 EU482814 1  1288 AY858039 3 
481 EU482815 1  1289 AB189125 3 
482 EU482816 1  1290 AB189126 3 
483 EU482817 1  1291 AB189127 3 
484 EU482818 1  1292 AB189128 3 
485 EU482819 1  1293 DQ675520 3 
486 EU482820 1  1294 DQ675521 3 
487 EU482821 1  1295 DQ675522 3 
488 EU482822 1  1296 DQ675523 3 
489 EU482823 1  1297 DQ675524 3 
490 EU482824 1  1298 DQ675525 3 
491 EU482825 1  1299 DQ675526 3 
492 EU482826 1  1300 DQ675527 3 
493 EU482827 1  1301 DQ675528 3 
494 EU482828 1  1302 DQ675530 3 
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495 EU482591 1  1303 DQ675531 3 
496 EU482592 1  1304 DQ675533 3 
497 EU482476 1  1305 AY858037 3 
498 EU482477 1  1306 AY496871 3 
499 EU482478 1  1307 AY496873 3 
500 EU482479 1  1308 AY496874 3 
501 EU482480 1  1309 AY496877 3 
502 EU482481 1  1310 EU687234 3 
503 EU482482 1  1311 EU482452 3 
504 EU482483 1  1312 EU482453 3 
505 EU482484 1  1313 EU482454 3 
506 EU482485 1  1314 EU482455 3 
507 EU482486 1  1315 EU482456 3 
508 EU482487 1  1316 EU482457 3 
509 EU482488 1  1317 EU482458 3 
510 EU482489 1  1318 EU482459 3 
511 EU482490 1  1319 EU482460 3 
512 EU482491 1  1320 EU482461 3 
513 EU482492 1  1321 EU482462 3 
514 EU482493 1  1322 EU482555 3 
515 EU482494 1  1323 EU529692 3 
516 EU482495 1  1324 EU482558 3 
517 EU482496 1  1325 EU482559 3 
518 EU482497 1  1326 EU482563 3 
519 EU482498 1  1327 EU529696 3 
520 EU482499 1  1328 EU529697 3 
521 EU482500 1  1329 EU482564 3 
522 EU482501 1  1330 EU529698 3 
523 EU482502 1  1331 EU529699 3 
524 EU482503 1  1332 EU482566 3 
525 EU482504 1  1333 EU529702 3 
526 EU482505 1  1334 EU529703 3 
527 EU482506 1  1335 EU529704 3 
528 EU482507 1  1336 EU529705 3 
529 EU482508 1  1337 EU529683 3 
530 EU482509 1  1338 EU529684 3 
531 EU482510 1  1339 FJ182015 3 
532 EU482511 1  1340 EU569688 3 
533 EU482512 1  1341 EU529685 3 
534 EU482513 1  1342 EU529686 3 
535 EU482514 1  1343 EU529687 3 
536 EU482515 1  1344 EU660407 3 
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537 EU482516 1  1345 EU660408 3 
538 EU482517 1  1346 EU660409 3 
539 EU482518 1  1347 EU660410 3 
540 EU482519 1  1348 EU660411 3 
541 EU482520 1  1349 EU596492 3 
542 EU482521 1  1350 EU596493 3 
543 EU482522 1  1351 EU596494 3 
544 EU482523 1  1352 EU687218 3 
545 EU482524 1  1353 EU726771 3 
546 EU482525 1  1354 EU726772 3 
547 EU482526 1  1355 FJ182013 3 
548 EU482527 1  1356 EU781136 3 
549 EU482528 1  1357 EU781137 3 
550 EU482529 1  1358 EU726773 3 
551 EU482530 1  1359 EU726774 3 
552 EU482531 1  1360 EU687219 3 
553 EU482532 1  1361 EU687221 3 
554 EU482533 1  1362 EU726768 3 
555 EU482534 1  1363 EU687226 3 
556 EU482535 1  1364 EU687196 3 
557 EU482536 1  1365 EU854298 3 
558 EU482537 1  1366 FJ373306 3 
559 EU482538 1  1367 EU687197 3 
560 EU482539 1  1368 EU687198 3 
561 EU482540 1  1369 EU726769 3 
562 AF513110 1  1370 EU687239 3 
563 AF226685 1  1371 FJ373303 3 
564 AF311956 1  1372 FJ373304 3 
565 AF311958 1  1373 EU854291 3 
566 AF311957 1  1374 EU854292 3 
567 AF309641 1  1375 FJ182004 3 
568 EU863650 1  1376 FJ024465 3 
569 DQ285562 1  1377 FJ024466 3 
570 FJ176779 1  1378 FJ024467 3 
571 FJ176780 1  1379 FJ024468 3 
572 FJ384655 1  1380 FJ024469 3 
573 EU280167 1  1381 FJ024470 3 
574 AF226687 1  1382 FJ024471 3 
575 EF122232 1  1383 FJ182005 3 
576 AF226686 1  1384 FJ373302 3 
577 EF122231 1  1385 FJ182006 3 
578 DQ193572 1  1386 FJ182007 3 
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579 DQ672556 1  1387 FJ182008 3 
580 DQ672557 1  1388 FJ182009 3 
581 DQ672558 1  1389 FJ182010 3 
582 DQ672559 1  1390 FJ182011 3 
583 EF032590 1  1391 FJ182037 3 
584 AF350498 1  1392 FJ182038 3 
585 AF298808 1  1393 FJ182039 3 
586 DQ672560 1  1394 FJ182040 3 
587 DQ672562 1  1395 FJ182041 3 
588 DQ672561 1  1396 FJ390371 3 
589 DQ672564 1  1397 FJ390372 3 
590 DQ672563 1  1398 FJ205870 3 
591 AB204803 1  1399 FJ390373 3 
592 AB074760 1  1400 FJ205871 3 
593 AY708047 1  1401 FJ390375 3 
594 AY713474 1  1402 FJ390376 3 
595 AY713475 1  1403 FJ390377 3 
596 AY722802 1  1404 FJ432722 3 
597 AY713476 1  1405 FJ432728 3 
598 AY726555 1  1406 FJ432731 3 
599 AY726554 1  1407 FJ562097 3 
600 AY722803 1  1408 FJ432741 3 
601 AY726549 1  1409 FJ562099 3 
602 AY726550 1  1410 FJ432743 3 
603 AY713473 1  1411 FJ562100 3 
604 AY722801 1  1412 FJ547061 3 
605 AY726551 1  1413 FJ547062 3 
606 AY726552 1  1414 FJ461322 3 
607 AY726553 1  1415 FJ562102 3 
608 EF457905 1  1416 FJ410229 3 
609 CS477263 1  1417 FJ461326 3 
610 CS477264 1  1418 FJ461329 3 
611 CS477265 1  1419 FJ547066 3 
612 CS479203 1  1420 FJ461334 3 
613 CS479204 1  1421 FJ461337 3 
614 FB667398 1  1422 FJ461338 3 
615 FB730116 1  1423 FJ562103 3 
616 GM059691 1  1424 FJ639712 3 
617 DQ285558 1  1425 FJ639713 3 
618 DQ285559 1  1426 FJ639714 3 
619 AY145123 1  1427 FJ639715 3 
620 AY145122 1  1428 FJ639716 3 
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621 AB195673 1  1429 FJ639719 3 
622 DQ285561 1  1430 FJ639720 3 
623 AY762084 1  1431 FJ639721 3 
624 AY732483 1  1432 FJ639722 3 
625 AY732482 1  1433 FJ639723 3 
626 AY732481 1  1434 FJ639724 3 
627 AY732480 1  1435 FJ639725 3 
628 AY732479 1  1436 FJ639726 3 
629 AY732478 1  1437 FJ639727 3 
630 AY732477 1  1438 FJ639728 3 
631 AY732476 1  1439 FJ639729 3 
632 AY732475 1  1440 FJ639730 3 
633 AY732474 1  1441 FJ639731 3 
634 EU848545 1  1442 FJ547069 3 
635 AY145121 1  1443 FJ547070 3 
636 NC_001477 1  1444 FJ562107 3 
637 U88535 1  1445 FJ547071 3 
638 U88537 1  1446 FJ410176 3 
639 EU359008 1  1447 FJ410177 3 
640 AY835999 1  1448 FJ547072 3 
641 EU081177 2  1449 FJ547073 3 
642 EU081178 2  1450 FJ547074 3 
643 EU081179 2  1451 FJ547075 3 
644 EU081180 2  1452 FJ547076 3 
645 DQ645543 2  1453 FJ547077 3 
646 DQ645544 2  1454 FJ547078 3 
647 DQ645545 2  1455 FJ547079 3 
648 DQ645546 2  1456 FJ547080 3 
649 AF100469 2  1457 FJ547081 3 
650 EU056810 2  1458 FJ547082 3 
651 DQ645547 2  1459 FJ547083 3 
652 DQ645548 2  1460 FJ410178 3 
653 M84727 2  1461 FJ547084 3 
654 NC_001474 2  1462 FJ478456 3 
655 M84728 2  1463 FJ547085 3 
656 DQ645549 2  1464 FJ639746 3 
657 DQ645550 2  1465 FJ639747 3 
658 DQ645551 2  1466 FJ639749 3 
659 DQ645552 2  1467 FJ639750 3 
660 DQ645553 2  1468 FJ639751 3 
661 DQ645554 2  1469 FJ639752 3 
662 DQ645555 2  1470 FJ639753 3 
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663 DQ645556 2  1471 FJ639754 3 
664 AF204178 2  1472 FJ639755 3 
665 AF204177 2  1473 FJ639756 3 
666 DQ645540 2  1474 FJ639757 3 
667 DQ645541 2  1475 FJ639758 3 
668 DQ645542 2  1476 FJ639759 3 
669 AB189122 2  1477 FJ639760 3 
670 AB189123 2  1478 FJ639761 3 
671 AB189124 2  1479 FJ639762 3 
672 AY858035 2  1480 FJ639763 3 
673 AJ487271 2  1481 FJ639765 3 
674 EU687249 2  1482 FJ639766 3 
675 EU482760 2  1483 FJ639767 3 
676 EU482445 2  1484 FJ639768 3 
677 EU482446 2  1485 FJ639769 3 
678 EU482447 2  1486 FJ639770 3 
679 EU482448 2  1487 FJ639771 3 
680 EU482449 2  1488 FJ639772 3 
681 EU482450 2  1489 FJ639774 3 
682 EU569721 2  1490 FJ639775 3 
683 EU482451 2  1491 FJ639776 3 
684 EU482544 2  1492 FJ639777 3 
685 EU482545 2  1493 FJ639778 3 
686 EU482546 2  1494 FJ639779 3 
687 EU482547 2  1495 FJ639780 3 
688 EU482548 2  1496 FJ639781 3 
689 EU482549 2  1497 FJ639782 3 
690 EU482550 2  1498 FJ639784 3 
691 EU482551 2  1499 FJ639785 3 
692 EU482552 2  1500 FJ639786 3 
693 EU482553 2  1501 FJ639787 3 
694 EU482554 2  1502 FJ639789 3 
695 EU482556 2  1503 FJ639790 3 
696 EU529693 2  1504 FJ639791 3 
697 EU482557 2  1505 FJ639792 3 
698 EU482560 2  1506 FJ639793 3 
699 EU482561 2  1507 FJ639795 3 
700 EU529694 2  1508 FJ639798 3 
701 EU529695 2  1509 FJ639799 3 
702 EU482562 2  1510 FJ639800 3 
703 EU660398 2  1511 FJ639801 3 
704 EU482565 2  1512 FJ639803 3 
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705 EU529700 2  1513 FJ639804 3 
706 EU529701 2  1514 FJ639805 3 
707 EU482604 2  1515 FJ639807 3 
708 EU482605 2  1516 FJ639810 3 
709 EU482606 2  1517 FJ639816 3 
710 EU482607 2  1518 FJ639817 3 
711 EU482608 2  1519 FJ639825 3 
712 EU569704 2  1520 FJ639826 3 
713 EU482568 2  1521 FJ639827 3 
714 EU482569 2  1522 EU482595 3 
715 EU482570 2  1523 EU482596 3 
716 EU482571 2  1524 EU529688 3 
717 EU482572 2  1525 EU482612 3 
718 EU482573 2  1526 EU660420 3 
719 EU482574 2  1527 EU482613 3 
720 EU482575 2  1528 EU529689 3 
721 EU482576 2  1529 EU529690 3 
722 EU482577 2  1530 EU529691 3 
723 EU482578 2  1531 EU569689 3 
724 EU482579 2  1532 EU482614 3 
725 EU482580 2  1533 EU569690 3 
726 EU482581 2  1534 EU569691 3 
727 EU482582 2  1535 EF629369 3 
728 EU482583 2  1536 EF629366 3 
729 EU482584 2  1537 EF629367 3 
730 EU482585 2  1538 EF629368 3 
731 EU482586 2  1539 EF629370 3 
732 EU482587 2  1540 AY679147 3 
733 EU482588 2  1541 AY876494 3 
734 EU482621 2  1542 AY923865 3 
735 EU569692 2  1543 EF643017 3 
736 EU569693 2  1544 AY858040 3 
737 FJ373300 2  1545 M93130 3 
738 EU596495 2  1546 AB214879 3 
739 EU660404 2  1547 AB214880 3 
740 EU482622 2  1548 AB214881 3 
741 EU569694 2  1549 AB214882 3 
742 EU596496 2  1550 DQ401690 3 
743 EU660405 2  1551 AY858043 3 
744 EU596497 2  1552 DQ401689 3 
745 EU569695 2  1553 DQ401691 3 
746 FJ373301 2  1554 DQ401692 3 
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747 EU569696 2  1555 DQ401693 3 
748 EU660406 2  1556 DQ401694 3 
749 EU569697 2  1557 DQ401695 3 
750 EU482623 2  1558 AY744677 3 
751 EU596498 2  1559 AY744678 3 
752 EU569698 2  1560 AY744679 3 
753 FJ478459 2  1561 AY744680 3 
754 EU596499 2  1562 AY744681 3 
755 EU569699 2  1563 AY744682 3 
756 EU569700 2  1564 AY744683 3 
757 EU569701 2  1565 AY744684 3 
758 EU621672 2  1566 AY744685 3 
759 EU569702 2  1567 AY496879 3 
760 EU482624 2  1568 AY858046 3 
761 EU596500 2  1569 AY766104 3 
762 EU482625 2  1570 AY648961 3 
763 FJ410291 2  1571 EU081181 3 
764 EU482626 2  1572 AY858047 3 
765 EU482627 2  1573 AY676353 3 
766 EU482628 2  1574 AY676352 3 
767 FJ639833 2  1575 AY676351 3 
768 EU482629 2  1576 AY676350 3 
769 FJ390390 2  1577 AY676349 3 
770 FJ390391 2  1578 AY676348 3 
771 FJ182014 2  1579 AY776329 3 
772 FJ547090 2  1580 AF375822 4 
773 EU482630 2  1581 AF326826 4 
774 EU569705 2  1582 AF326573 4 
775 EU482589 2  1583 AF289029 4 
776 EU569706 2  1584 FJ024424 4 
777 EU569707 2  1585 EU854295 4 
778 EU660399 2  1586 EU854296 4 
779 EU569708 2  1587 EU854297 4 
780 EU569709 2  1588 EU854299 4 
781 EU596485 2  1589 FJ182016 4 
782 EU569710 2  1590 EU854300 4 
783 EU596486 2  1591 FJ182017 4 
784 EU687212 2  1592 EU854301 4 
785 EU660400 2  1593 FJ024476 4 
786 EU569711 2  1594 FJ639736 4 
787 EU569712 2  1595 FJ639737 4 
788 EU596487 2  1596 FJ639738 4 
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789 EU569713 2  1597 FJ639739 4 
790 EU569714 2  1598 FJ639742 4 
791 EU569715 2  1599 FJ639744 4 
792 EU569716 2  1600 FJ639745 4 
793 EU569717 2  1601 FJ639748 4 
794 EU569718 2  1602 FJ639764 4 
795 EU569719 2  1603 FJ639773 4 
796 EU569720 2  1604 FJ226067 4 
797 EU596488 2  1605 AY947539 4 
798 EU596489 2  1606 EF457906 4 
799 EU596490 2  1607 NC_002640 4 
800 EU596491 2  1608 AF326827 4 
801 EU677141 2  1609 AY618989 4 
802 EU677142 2  1610 AY618991 4 
803 EU677143 2  1611 AY618990 4 
804 EU677144 2  1612 AY618988 4 
805 EU677145 2  1613 AY618992 4 
806 EU677146 2  1614 AY618993 4 
807 EU677147 2  1615 M14931 4 





Table A.2.  List of CTL epitopes retrieved from the Immune Epitope Database. 
 
Epitopes Protein Start End Serotype 
1 RVSTVQQLTK AnchC 22 31 2 
2 GPMKLVMAF AnchC 42 50 1, 3 
3 GPMKLVMAFI AnchC 42 51 1, 3 
4 KLVMAFIAFLRFL AnchC 45 57 1, 3 
5 LFMALVAFLRFLTIP AnchC 46 60 2 
6 VLAFITFLR AnchC 47 55 4 
7 FMALVAFLRF AnchC 47 56 2 
8 MAFIAFLRF AnchC 48 56 1, 3 
9 IAFLRFLAI AnchC 51 59 1, 3 
10 TIKKSKAINVLRGFR AnchC 71 85 2 
11 KSGAIKVLK AnchC 74 82 3 
12 LRGFKKEISNML AnchC 81 92 1, 3 
13 LRGFRKEIGRML AnchC 81 92 2 
14 LKGFKKEISNML AnchC 81 92 3 
15 LIGFRKEIGRML AnchC 81 92 4 
16 FRKEIGRML AnchC 84 92 2, 4 
17 ISSMLNIMNR AnchC 88 97 1 
18 ITLLCLIPTV AnchC 103 112 4 
19 VTLLCLIPTV AnchC 103 112 4 
20 TLLCLIPTV AnchC 104 112 4 
21 CLMMMLPATL AnchC 104 113 3 
22 LMMMLPATL AnchC 105 113 3 
23 LMMILPAAL AnchC 105 113 3 
24 LMMMLPATLA AnchC 105 114 3 
25 MMMLPATLA AnchC 106 114 3 
26 MMMLPATLAF AnchC/prM 106 115 3 
27 MLIPTAMAF AnchC/prM 107 115 2 
28 MMLPATLAF AnchC/prM 107 115 3 
29 CLIPTAMAF AnchC/prM 107 115 4 
30 IPTVMAFHL AnchC/prM 109 117 2, 4 
31 TLMAMDLGEL prM 149 158 2 
32 VTYECPLLV prM 163 171 4 
33 MSSEGAWKHA prM 225 234 2, 4 
34 QRIETWILRHPGFTM prM 235 249 2 
35 WILRHPGFTMMAAIL prM 240 254 2 
36 HPGFTILALF prM 244 253 3 
37 FTIMAAILAY prM 247 256 2 
38 FTILALFLAH prM 247 256 3 
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39 TLMAAILAY prM 248 256 2 
40 TIMAAILAY prM 248 256 2 
41 LAYTIGTTHF prM 254 263 2 
42 LLMLVTPSM prM 271 279 1, 3 
43 MLVTPSMTM prM/E 273 281 1, 3 
44 KPTLDFELI E 318 326 2, 4 
45 LDFELIKTEAKQPAT E 321 335 2 
46 LKTEVTNPAV E 326 335 1 
47 CPTQGEATL E 354 362 1, 3 
48 CPTQGEPSL E 354 362 2 
49 CPTQGEAVL E 354 362 3 
50 LPEEQDQNY E 362 370 3 
51 WGNGCGLFGKGGIVT E 381 395 2 
52 EPIEGKVVQY E 403 412 3 
53 YENLKYSVI E 412 420 1 
54 MENKAWLVHRQWFLD E 481 495 2 
55 WLVHRQWFLDLPLPW E 486 500 2 
56 FFDLPLPWT E 493 501 3 
57 FLDLPLPWL E 493 501 2 
58 FLDLPLPWT E 493 501 1, 3, 4 
59 LPLPWTSGA E 496 504 1, 3 
60 LPLPWLPGAD E 496 505 2 
61 LPGADTQGSN E 501 510 2 
62 TLVTFKNPHAKKQDV E 516 530 2 
63 TFKVPHAKR E 519 527 4 
64 KNPHAKKQDVVVLGS E 521 535 2 
65 KKQDVVVLGSQEGAM E 527 540 2 
66 QEGAMHTAL E 536 544 1, 2, 3 
67 QEGAMHSAL E 536 544 4 
68 MSYTMCSGK E 577 585 4 
69 MSYSMCTGKF E 577 586 2 
70 SPCKIPFEIM E 611 620 2 
71 IPFEIMDLEK E 615 624 2 
72 RDVNKEKVVGRVISSTPLAE E 620 639 4 
73 IVIGVGDSAL E 658 667 4 
74 EPGQLKLNWF E 663 672 2 
75 SSIGKMFEATARG E 676 688 1 
76 RMAILGDTAWDFGSL E 691 705 2 
77 MAILGDTAW E 692 700 1, 2, 3 
78 ILGDTAWDFG E 694 703 1, 2, 3 
79 LIHQVFGTAY E 715 724 1 
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80 LVHQIFGTAY E 715 724 1 
81 FGAIYGAAF E 720 729 2 
82 YGVLFSGVSW E 724 733 1 
83 SWMVRILIGF E 732 741 4 
84 KILIGVIITWIGMNS E 736 750 2 
85 IGIGILLTW E 737 745 1, 3 
86 IGIGVLLTW E 737 745 1, 3 
87 MAMTCIAVG E 755 763 4 
88 SLVLVGVVTL E 758 767 2 
89 VQADMGCVV E/NS1 773 781 3, 4 
90 SPKRLATAIA NS1 813 822 3 
91 KQIANELNY NS1 844 852 3 
92 KQISNELNY NS1 844 852 1 
93 IMTGDIKGIMQA NS1 863 874 2 
94 LKYSWKTWGKAKMLS NS1 886 900 2 
95 TPEARNSTF NS1 900 908 4 
96 TPEAKNSTF NS1 900 908 4 
97 GVFTTNIWLKLKEKQ NS1 936 950 2 
98 VYTQLCDHR NS1 949 957 3 
99 VYTQLCDHRL NS1 949 958 3 
100 NRAVHADMGYWIESA NS1 966 980 2 
101 KAVHADMGYW NS1 967 976 1, 3 
102 RAVHADMGYW NS1 967 976 1, 2, 3, 4 
103 MGYWIESAL NS1 973 981 2 
104 LNDTWKIEKASFIEV NS1 981 995 2 
105 RASFIEVKTC NS1 989 998 1 
106 IPKAYAGPF NS1 1018 1026 4 
107 YGGPISQHNY NS1 1022 1031 1 
108 FAGPVSQHNY NS1 1022 1031 2 
109 RPGYHTQTA NS1 1032 1040 2, 3 
110 GPWHLGKLEL NS1 1041 1050 1, 3 
111 GPWHLGKLEM NS1 1041 1050 2, 4 
112 GPSLRTTTV NS1 1070 1078 1, 3 
113 RYMGEDGCWY NS1 1097 1106 3 
114 RPISEKEENM NS1 1111 1120 3 
115 FTMGVLCLAI NS2A 1135 1144 3 
116 RVGTKHAILLVAVSF NS2A 1153 1167 2 
117 HMIAGVLFTF NS2A 1158 1167 3 
118 MSFRDLGRVM NS2A 1175 1184 2 
119 RDLGRVMVMVGATMT NS2A 1178 1192 2 
120 TYLALIATF NS2A 1200 1208 1, 3 
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121 IQPFLALGF NS2A 1210 1218 3 
122 GFFLRKLTSR NS2A 1217 1226 3 
123 LMMTTIGVVL NS2A 1228 1237 2 
124 LMMATIGIAL NS2A 1228 1237 2 
125 MMATIGIAL NS2A 1229 1237 2 
126 MMLKLLTDF NS2A 1259 1267 1 
127 HQLWATLLSL NS2A 1270 1279 1 
128 YQLAVTITAI NS2A 1270 1279 2 
129 YQLWTALISL NS2A 1270 1279 3 
130 TTFSLHYAW NS2A 1284 1292 1 
131 MPLVMAWRTI NS2A 1286 1295 4 
132 AMALSIVSLF NS2A 1296 1305 1 
133 MALSIVSLF NS2A 1297 1305 1 
134 GASKRSWPLN NS2A/NS2B 1342 1351 4 
135 MAVGMVSIL NS2B 1355 1363 2 
136 IPMTGPLVAG NS2B 1372 1381 2 
137 GPLVAGGLL NS2B 1376 1384 2, 3 
138 ELERAADVK NS2B 1398 1406 2 
139 SPILSITISE NS2B 1417 1426 2 
140 ILIRTGLLVI NS2B 1443 1452 2 
141 ISGLFPVSIPITAAA NS2B 1452 1466 2 
142 FPVSIPITAA NS2B 1456 1465 2 
143 IPITAAAWY NS2B 1460 1468 2 
144 ITAAAWYLW NS2B 1462 1470 2 
145 YRILQRGLLGRSQ NS3 1499 1511 1 
146 RIKQKGIL NS3 1500 1507 2 
147 SQIGAGVYK NS3 1510 1518 2 
148 QKEGVFHTMW NS3 1517 1526 3 
149 KEGVFHTMW NS3 1518 1526 3 
150 MEGVFHTMW NS3 1518 1526 4 
151 MEGVFHTMWH NS3 1518 1527 4 
152 TFHTMWHVTRGAVLM NS3 1521 1535 2 
153 VTRGAVLMHK NS3 1528 1537 2 
154 RIEPSWADVK NS3 1540 1549 2 
155 SVKKDLISY NS3 1547 1555 1, 3 
156 DVKKDLISY NS3 1547 1555 2 
157 GGWRLSAQW NS3 1557 1565 3 
158 EGEWKEGEEVQVLAL NS3 1562 1576 2 
159 AVQTKPGLFK NS3 1584 1593 2 
160 MPGTFQTTTG NS3 1588 1597 3 
161 GEVGAIALDF NS3 1597 1606 1 
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162 KPGTSGSPI NS3 1607 1615 1, 3, 4 
163 KPGTSGSPIV NS3 1607 1616 1 
164 KPGTSGSPII NS3 1607 1616 3, 4 
165 SPGTSGSPIIDKKGK NS3 1607 1621 2 
166 GTSGSPIADK NS3 1609 1618 2 
167 GTSGSPIIDK NS3 1609 1618 2 
168 GTSGSPIINR NS3 1609 1618 3, 4 
169 GTSGSPIVDK NS3 1609 1618 2 
170 GTSGSPIVDR NS3 1609 1618 2 
171 GTSGSPIVNR NS3 1609 1618 1 
172 GTSGSPIADKK NS3 1609 1619 2 
173 GTSGSPIIDKK NS3 1609 1619 2 
174 GTSGSPIINRE NS3 1609 1619 3 
175 GTSGSPIINRK NS3 1609 1619 4 
176 TSGSPIIDK NS3 1610 1618 2 
177 SPIINREGKV NS3 1613 1622 3 
178 DKKGKVVGL NS3 1617 1625 2 
179 NREGKIVGLYGNGVV NS3 1617 1631 1, 3 
180 NREGKVVGLYGNGVV NS3 1617 1631 1, 3 
181 DKKGKVVGLYGNGVV NS3 1617 1631 2 
182 KVVGLYGNGVVTRSG NS3 1621 1635 2 
183 VIGLYGNGV NS3 1622 1630 4 
184 YVSAIAQTEK NS3 1637 1646 2 
185 EPDYEVDEDI NS3 1649 1659 4 
186 NPEIEDDIF NS3 1652 1660 2 
187 RNLTIMDLHPGSGKT NS3 1663 1677 1, 3 
188 RKLTIMDLHPGSGKT NS3 1663 1677 1, 3 
189 RKLTIMDLHPGAGKT NS3 1663 1677 2 
190 KRLTIMDLHPGAGKT NS3 1663 1677 2, 4 
191 HPGAGKTKRY NS3 1671 1680 2 
192 TKRYLPAIVREAIKR NS3 1677 1691 1, 2 
193 RKYLPAIVRE NS3 1678 1687 1, 3 
194 KRYLPAIVREAIKRG NS3 1678 1692 2 
195 LPAIVREAI NS3 1681 1689 1, 2, 3 
196 AIVREAIKR NS3 1683 1691 1, 2, 3 
197 AIKRGLRTL NS3 1688 1696 2 
198 LAPTRVVAAEME NS3 1698 1709 2, 3, 4 
199 LAPTRVVAAEMEEAL NS3 1698 1712 2, 3, 4 
200 APTRVVAAEM NS3 1699 1708 1, 2, 3, 4 
201 APTRVVASEM NS3 1699 1708 1 
202 PTRVVASEMAEALKG NS3 1700 1714 1 
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203 PTRVVAAEMEEALRG NS3 1700 1714 2, 4 
204 PTRVVAAEMEEAMKG NS3 1700 1714 3 
205 TRVVAAEMEEA NS3 1701 1711 2, 3, 4 
206 SEMAEALKGM NS3 1706 1715 1 
207 MEEALRGLPIRYQTP NS3 1708 1722 2, 4 
208 EALRGLPIR NS3 1710 1718 2, 3, 4 
209 ALRGLPIRY NS3 1711 1719 2, 3, 4 
210 AMKGLPIRY NS3 1711 1719 3 
211 LPIRYQTPA NS3 1715 1723 2, 4 
212 LPIRYQTPAI NS3 1715 1724 2 
213 PIRYQ NS3 1716 1720 1, 2, 3, 4 
214 IRYQTTATK NS3 1717 1725 3 
215 EHTGREIVDLMCHAT NS3 1727 1741 1, 2, 3, 4 
216 HTGREIVDLMCHATF NS3 1728 1742 1, 2, 3, 4 
217 EIVDLMCHAT NS3 1732 1741 1, 2, 3, 4 
218 EIVDLMCHATFTMRL NS3 1732 1746 1, 2, 3 
219 VDLMCHATFT NS3 1734 1743 1, 2, 3, 4 
220 LMCHATFTM NS3 1736 1744 1, 2, 3 
221 LLSPVRVPNY NS3 1746 1755 1, 2, 3 
222 SPVRVPNYNL NS3 1748 1757 2, 3 
223 VPNYNMIIM NS3 1752 1760 1 
224 PNYNLIIMDEAHFTD NS3 1753 1767 2, 3 
225 DPASIAARGY NS3 1767 1776 1, 2, 3 
226 PASIAARGYI NS3 1768 1777 1, 2, 3 
227 STRVEMGEAAGIFMT NS3 1778 1792 2 
228 GMGEAAAIF NS3 1782 1790 1, 3 
229 TPPGSRDPF NS3 1794 1802 2 
230 FPQSNAPIM NS3 1802 1810 2 
231 FPQSNAPIMD NS3 1802 1811 2 
232 APIMDEEREI NS3 1807 1816 2 
233 EERDIPERSW NS3 1812 1821 1, 3 
234 EREIPERSWNSGHEW NS3 1813 1827 2 
235 REIPERSWNT NS3 1814 1823 2, 4 
236 RSWNSGHEW NS3 1819 1827 1, 2 
237 GNEWITDFVGKTVWF NS3 1824 1838 3 
238 WITDFVGKTVW NS3 1827 1837 3 
239 VTDFKGKTVWFVPSI NS3 1828 1842 2 
240 TVWFVPSIK NS3 1835 1843 1, 2, 3, 4 
241 KVIQLSRKTF NS3 1858 1867 2, 3, 4 
242 YPKTKLTDW NS3 1871 1879 4 
243 YPKTKLTDWD NS3 1871 1880 4 
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244 RVIDPRRCL NS3 1898 1906 1, 3, 4 
245 RVIDPRRCM NS3 1898 1906 2 
246 RVIDPRRCMK NS3 1898 1907 2 
247 RVIDPRRCLK NS3 1898 1907 1, 3, 4 
248 DPRRCLKPV NS3 1901 1909 1, 3, 4 
249 MPVTHSSAA NS3 1924 1932 2 
250 MPVTVASAAQ NS3 1924 1933 1, 3 
251 MPVTHSSAAQ NS3 1924 1933 2 
252 NPAQEDDQY NS3 1941 1949 4 
253 QYIFTGQPL NS3 1948 1956 3 
254 DNINTPEGIIPSMFE NS3 1973 1987 2 
255 YTPEGIIPTL NS3 1976 1985 4 
256 TPEGIIPAL NS3 1977 1985 1, 3 
257 TPEGIIPSL NS3 1977 1985 2 
258 TPEGIIPSM NS3 1977 1985 2 
259 TPEGIIPTL NS3 1977 1985 4 
260 TPEGIIPALF NS3 1977 1986 1, 3 
261 TPEGIIPSMF NS3 1977 1986 2 
262 TPEGIIPTLF NS3 1977 1986 4 
263 GEFRLRGEQR NS3 1998 2007 4 
264 RLRGEARKTF NS3 2001 2010 1, 2 
265 RGEARKTFVDLMRRG NS3 2003 2017 2 
266 GESRKTFVE NS3 2004 2012 3 
267 GEARKTFVDL NS3 2004 2013 1, 2 
268 GEARKTFVEL NS3 2004 2013 1, 2 
269 GESRKTFVEL NS3 2004 2013 3 
270 GEQRKTFVEL NS3 2004 2013 4 
271 KTFVDLMRR NS3 2008 2016 2 
272 ELMRRGDLPV NS3 2012 2021 1, 2, 3, 4 
273 LMRRGDLPVWLAYRV NS3 2013 2027 2 
274 LPVWLSYKV NS3 2019 2027 1, 4 
275 LPVWLAYRV NS3 2019 2027 2 
276 LPVWLAYKV NS3 2019 2027 2, 3 
277 LPVWLAYRVA NS3 2019 2028 2 
278 LPVWLAYKVA NS3 2019 2028 2, 3 
279 LPVWLAHKVA NS3 2019 2028 3 
280 YKVASAGISY NS3 2025 2034 4 
281 AAEGINYADRRWCFD NS3 2028 2042 2 
282 INYADRRWCF NS3 2032 2041 2 
283 FQYSDRRWCF NS3 2032 2041 1 
284 KYTDRKWCF NS3 2033 2041 3 
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285 NYADRKWCF NS3 2033 2041 2 
286 NYADRRWCF NS3 2033 2041 2 
287 QYSDRRWCF NS3 2033 2041 1 
288 SYKDREWCF NS3 2033 2041 4 
289 REWCFTGERN NS3 2037 2046 4 
290 EENMDVEIW NS3 2051 2059 1, 3 
291 KEGERKKLRPRWLDA NS3 2061 2075 1, 3 
292 KEGERKKLKPRWLDA NS3 2061 2075 2 
293 KEGEKKKLRPRWLDA NS3 2061 2075 3 
294 RPRWLDART NS3 2069 2077 1, 3 
295 KPRWLDARI NS3 2069 2077 2 
296 LDARIYSDPLALKEF NS3 2073 2087 2 
297 MALKDFKEF NS3 2082 2090 4 
298 EFKEFAAGR NS3 2086 2094 1, 2 
299 EFKEFAAGRR NS3 2086 2095 1 
300 FASGRKSITL NS3/NS4A 2090 2099 4 
301 LPTFMTQKAR NS4A 2108 2117 2 
302 LPTYLSSRAK NS4A 2108 2117 4 
303 MTQKARNAL NS4A 2112 2120 2 
304 TAEAGGRAY NS4A 2128 2136 2 
305 ALSELPETL NS4A 2139 2147 2 
306 LPESLETLM NS4A 2143 2151 4 
307 LPETLETLLL NS4A 2143 2152 2 
308 LETLMLVAL NS4A 2147 2155 4 
309 LETLMLVALL NS4A 2147 2156 4 
310 TLMLLALIAV NS4A 2149 2158 1 
311 LMLLALIAVL NS4A 2150 2159 1 
312 LLLLTLLATV NS4A 2150 2159 2 
313 LLLGLMILL NS4A 2151 2159 3 
314 LLLTLLATV NS4A 2151 2159 2 
315 MLLALIAVL NS4A 2151 2159 1 
316 MLVALLGAM NS4A 2151 2159 4 
317 GAMLFLISGK NS4A 2162 2171 3 
318 LSMGLITIAV NS4A 2176 2185 4 
319 MASSALLWMA NS4A 2184 2193 1 
320 ASSVLLWMAS NS4A 2185 2194 1 
321 VASGLLWVAE NS4A 2185 2194 4 
322 MLWMAEIPL NS4A 2189 2197 3 
323 WVAEIQPQW NS4A 2191 2199 4 
324 YAQIQPHWI NS4A 2192 2200 2 
325 MAEIPLQWI NS4A 2192 2200 3 
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326 QPHWIAASI NS4A 2196 2204 2 
327 QPHWIAASII NS4A 2196 2205 2 
328 SIILEFFLMV NS4A 2203 2212 1, 4 
329 IILEFFLMV NS4A 2204 2212 1, 2, 4 
330 IILEFFLMVL NS4A 2204 2213 1, 2, 4 
331 FLMVLLIPEP NS4A 2209 2218 1, 2, 4 
332 TPQDNQLAY 2K 2223 2231 1, 3 
333 TPQDNQLTY 2K 2223 2231 2 
334 TPQDNQLAYV 2K 2223 2232 1, 3 
335 NQLIYVILTI 2K 2227 2236 4 
336 MANEMGFLEK 2K/NS4B 2244 2253 2 
337 LEKTKKDL NS4B 2251 2258 2 
338 TTKRDLGMSK NS4B 2253 2262 3 
339 KTDFGFYQV NS4B 2255 2263 4 
340 EPGVVSPTSY NS4B 2263 2273 3 
341 QPESNILDI NS4B 2268 2276 2 
342 TETTILDVDL NS4B 2269 2278 4 
343 RPASAWTLY NS4B 2279 2287 1, 2, 4 
344 HPASAWTLY NS4B 2279 2287 1, 3 
345 RPASAWTLYA NS4B 2279 2288 1, 2, 4 
346 PASAWTLYAV NS4B 2280 2289 1, 2, 3, 4 
347 TLYAVATTI NS4B 2285 2293 1, 3, 4 
348 VATTFVTPM NS4B 2289 2297 2 
349 ITPMLRHTI NS4B 2294 2302 1, 3 
350 TPMLRHTIEN NS4B 2295 2304 1, 3, 4 
351 IANQAAILM NS4B 2314 2322 1 
352 IANQATVLM NS4B 2314 2322 2 
353 VPLLAIGCY NS4B 2337 2345 2 
354 VPLLAMGCY NS4B 2337 2345 4 
355 NPLTLTAAV NS4B 2349 2357 1, 3 
356 NPITLTAAL NS4B 2349 2357 2 
357 TLTAAVLLLV NS4B 2352 2361 3 
358 LTAAVLLLI NS4B 2353 2361 3 
359 TAAVLLLITH NS4B 2354 2363 3 
360 AAVLLLVTHY NS4B 2355 2364 3 
361 LVMLLVHYA NS4B 2357 2365 4 
362 VLMLVAHYA NS4B 2357 2365 1 
363 VLLLVTHYA NS4B 2357 2365 3 
364 VLLLVTHYAI NS4B 2357 2366 3 
365 FLLVAHYAI NS4B 2358 2366 2 
366 AIIGPGLQAK NS4B 2365 2374 1, 2, 3, 4 
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367 KATREAQKRA NS4B 2374 2383 2 
368 NPTVDGITV NS4B 2390 2398 2, 4 
369 VTIDLDPVVY NS4B 2397 2406 1 
370 TVIDLDPIPYDPKFE NS4B 2397 2411 2 
371 DPIPYDPKF NS4B 2402 2410 2 
372 EPISYDPKF NS4B 2402 2410 4 
373 MLLILCVTQV NS4B 2418 2427 2 
374 LILCVTQVLM NS4B 2420 2429 2 
375 ILLMRTTWA NS4B 2427 2435 1 
376 LLLMRTSWA NS4B 2427 2435 3 
377 LLLMRTTWA NS4B 2427 2435 4 
378 WALCESITL NS4B 2434 2442 1 
379 CEALTLATGPISTLW NS4B 2437 2451 2 
380 LATGPVLTLW NS4B 2442 2451 4 
381 ATGPLTTLW NS4B 2443 2451 1 
382 ATGPISTLW NS4B 2443 2451 2 
383 ATGPITTLW NS4B 2443 2451 3 
384 ATGPILTLW NS4B 2443 2451 4 
385 ATGPVLTLW NS4B 2443 2451 4 
386 LWEGSPGKF NS4B 2450 2458 1, 3 
387 SPGKFWNTTI NS4B 2454 2463 1, 3 
388 IAVSMANIF NS4B 2463 2471 1, 2, 3 
389 IAVSTANIF NS4B 2463 2471 4 
390 MANIFRGSY NS4B 2467 2475 1, 2, 3 
391 YLAGAGLAF NS4B 2475 2483 1, 3, 4 
392 SRLNALGKSEFQI NS5 2509 2521 2 
393 KKLNQLSRKEFDL NS5 2509 2521 3 
394 ETTKHAVSR NS5 2543 2551 1 
395 ETTHHAVSR NS5 2543 2551 3 
396 GSSKIRWIVE NS5 2552 2561 4 
397 GPGHEEPIPM NS5 2601 2610 1, 2, 4 
398 IPMATYGWNL NS5 2608 2617 1, 4 
399 IPMSTYGWNL NS5 2608 2617 2 
400 MSTYGWNIVK NS5 2610 2619 3 
401 MATYGWNLVK NS5 2610 2619 1, 4 
402 MSTYGWNLVRLQSGV NS5 2610 2624 2 
403 STYGWNIVK NS5 2611 2619 3 
404 ATYGWNLVK NS5 2611 2619 1, 4 
405 STYGWNLVR NS5 2611 2619 2 
406 QSGVDVFFTP NS5 2621 2630 2 
407 DVFFTPPEK NS5 2625 2633 1, 2 
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408 ESSSNPTIEE NS5 2643 2652 1, 4 
409 SPSPTVEESR NS5 2645 2654 3 
410 TLRVLNLVENWLNNN NS5 2655 2669 2 
411 LRVLNLVENW NS5 2656 2665 2 
412 RVLKMVEPW NS5 2657 2665 1, 3, 4 
413 KVLNPYMPSV NS5 2675 2684 1, 2 
414 VLNPYMPSV NS5 2676 2684 1, 2 
415 MPSVIEKMET NS5 2681 2690 2 
416 LSRNSTHEM NS5 2704 2712 1, 2, 3, 4 
417 SRNSTHEMY NS5 2705 2713 1, 2, 3, 4 
418 VSSVNMVSRL NS5 2723 2732 3 
419 MVSRLLLNR NS5 2728 2736 3 
420 FTMRHKKATY NS5 2737 2746 2 
421 SWHYDQDHPYKTWAY NS5 2785 2799 2 
422 WHYDQDHPY NS5 2786 2794 2 
423 QENPYRTWAY NS5 2790 2799 4 
424 KTWAYHGSY NS5 2795 2803 1, 2, 3 
425 KTWAYHGSYETKQTG NS5 2795 2809 2 
426 WAYHGSYEV NS5 2797 2805 1, 3 
427 WAYHGSYET NS5 2797 2805 2 
428 ASSMVNGVVR NS5 2811 2820 1, 2 
429 ASSMVNGVVK NS5 2811 2820 1, 2, 4 
430 RLLTKPWDVVPMVTQ NS5 2820 2834 2 
431 KPWDIIPMV NS5 2824 2832 2 
432 KPWDVIPMV NS5 2824 2832 1, 2, 4 
433 KPWDVLPMV NS5 2824 2832 2 
434 KPWDVLPTV NS5 2824 2832 2 
435 KPWDVVPMV NS5 2824 2832 2, 3, 4 
436 KPWDVVPTV NS5 2824 2832 3 
437 VPMVTQMAM NS5 2829 2837 2, 3 
438 QIAMTDTTPF NS5 2834 2843 1 
439 MAMTDTTPFGQQRVF NS5 2835 2849 1, 2, 3 
440 DTTPFGQQR NS5 2839 2847 1, 2, 3, 4 
441 TPFGQQRVF NS5 2841 2849 1, 2, 3, 4 
442 TPRSMPGTRR NS5 2857 2866 3 
443 EPKEGTKKLM NS5 2859 2868 2 
444 MPGTRRVMGI NS5 2861 2870 3 
445 LMKITAEWLW NS5 2867 2876 2 
446 VMGITAEWLW NS5 2867 2876 3 
447 MKITAEWLW NS5 2868 2876 2 
448 MEITAEWLW NS5 2868 2876 3 
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449 MTTTANWLW NS5 2868 2876 4 
450 KITAEWLWK NS5 2869 2877 2 
451 GKKKTprMCTREEFT NS5 2880 2894 2 
452 KPRICTREEF NS5 2884 2893 1 
453 NPRLCTREEF NS5 2884 2893 4 
454 TprMCTREEF NS5 2884 2893 2 
455 RPRLCTREEF NS5 2884 2893 3 
456 KPRLCTREEF NS5 2884 2893 3, 4 
457 RAAVEDEEF NS5 2917 2925 3 
458 EAVEDSRFWE NS5 2918 2927 2 
459 KAKGSRAIW NS5 2961 2969 1, 2, 3 
460 RAKGSRAIW NS5 2961 2969 4 
461 KGSRAIWYMW NS5 2963 2972 1, 2, 3, 4 
462 GSRAIWYMW NS5 2964 2972 1, 2, 3, 4 
463 RFLEFEALGF NS5 2976 2985 1, 2, 3, 4 
464 RYLEFEALGF NS5 2976 2985 3 
465 LEFEALGFM NS5 2978 2986 1 
466 LEFEALGFL NS5 2978 2986 1 
467 LEFEALGFMN NS5 2978 2987 2, 3, 4 
468 LEFEALGFLN NS5 2978 2987 2, 3, 4 
469 LGFLNEDHW NS5 2983 2991 2, 3, 4 
470 FSRENSLSGV NS5 2992 3001 1, 2 
471 GEGLHKLGY NS5 3003 3011 1, 2, 3 
472 YILRDVSKK NS5 3011 3019 2 
473 HALLATSIF NS5 3055 3063 1 
474 HKKLAEAIFKLTYQN NS5 3055 3069 2 
475 RQLANAIFK NS5 3056 3064 3 
476 KLAEAIFKL NS5 3057 3065 2 
477 YQNKVVKVLR NS5 3067 3076 4 
478 YQNKVVKVQR NS5 3067 3076 3 
479 RPTPKGAVM NS5 3076 3084 4 
480 RPTPKGTVM NS5 3076 3084 2, 3 
481 TPRGTVMDII NS5 3078 3087 2 
482 TPKGAVMDII NS5 3078 3087 4 
483 FTNMEAQLVR NS5 3106 3115 1, 3 
484 RQMEGEGIF NS5 3115 3123 2 
485 RQMEGEGVL NS5 3115 3123 3 
486 TITEEIAVQ NS5 3130 3139 2 
487 KVRKDIQQW NS5 3181 3189 2 
488 IPQWEPSKGW NS5 3186 3195 1, 4 
489 FMKDGRSLVV NS5 3212 3221 4 
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490 KETACLGKSY NS5 3244 3253 1, 2 
491 RETACLGKSY NS5 3244 3253 1, 2 
492 RETACLGKAY NS5 3244 3253 3, 4 
493 ETACLGKSY NS5 3245 3253 1, 2 
494 ETACLGKAY NS5 3245 3253 3, 4 
495 ETACLGKSYA NS5 3245 3254 1, 2 
496 ETACLGKAYA NS5 3245 3254 3, 4 
497 KSYAQMWQL NS5 3251 3259 1 
498 KAYAQMWSL NS5 3251 3259 3, 4 
499 KSYAQMWSLMYFHRR NS5 3251 3265 2 
500 SYAQMWTLMY NS5 3252 3261 2 
501 YAQMWQLMY NS5 3253 3261 1 
502 YAQMWTLMY NS5 3253 3261 2, 3 
503 YAQMWSLMY NS5 3253 3261 2, 3, 4 
504 YAQMWQLMYF NS5 3253 3262 1 
505 YAQMWTLMYF NS5 3253 3262 2, 3 
506 YAQMWSLMYF NS5 3253 3262 2, 3, 4 
507 AQMWTLMYF NS5 3254 3262 2, 3 
508 ICSAVPVHW NS5 3274 3282 3 
509 PTSRTTWSIH NS5 3284 3293 1, 2, 3, 4 
510 WSIHAHHQW NS5 3290 3298 1, 3, 4 
511 NPWMEDKTH NS5 3316 3324 1 
512 NPWMEDKTPV NS5 3316 3325 2, 3 
513 NPNMIDKTPV NS5 3316 3325 4 
514 MIDKTPVHSW NS5 3319 3328 4 
515 TPVHSWEDI NS5 3323 3331 4 
516 VPYLGKREDQ NS5 3331 3340 1, 2, 3 
517 REDQWCGSL NS5 3337 3345 1, 2, 3 
518 REDLWCGSL NS5 3337 3345 4 
519 IGLTSRATW NS5 3346 3354 2, 3, 4 
520 NIQTAINQV NS5 3357 3365 2 
521 NEEYTDYMPSMKRFR NS5 3371 3385 2 
522 DYMPSMKRFR NS5 3376 3385 2, 3 
523 MPSMKRFRRE NS5 3378 3387 2 
524 MPVMKRYSAP NS5 3378 3387 4 
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Figure A.1.  Median gene diversity at synonymous and nonsynonymous polymorphic sites in CTL epitope (Ep) and non-CTL epitope 
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Figure A.2.  Median gene diversity at synonymous and nonsynonymous polymorphic sites in CTL epitope (Ep) and non-CTL epitope 
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Figure A.3.  Median gene diversity at synonymous and nonsynonymous polymorphic sites in CTL epitope (Ep) and non-CTL epitope 
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Figure A.4.  Median gene diversity at synonymous and nonsynonymous polymorphic sites in CTL epitope (Ep) and non-CTL epitope 
(NonEp) regions of the 11 proteins of DENV4 (Kruskal-Wallis test * P<0.05, ** P<0.01, *** P<0.001). 
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APPENDIX B – CHAPTER 3 SUPPLEMENTARY INFORMATION 
Table B.1.  GenBank accession numbers for complete genome sequences retrieved from 
the Dengue Virus Database containing the highest percentage of epitope coverage.  If 
more than one accession number is listed, these sequences contained equivalent 
percentages of epitope coverage across the genome. 
Serotype 

















Table B.2a.  Counts used to determine RANK measures at top 25% of prediction results between each pair of programs tested for all 
four DENV serotypes individually as well as all serotypes combined (* P<0.05, ** P<0.01, *** P<0.001). 
 
Serotype IEDB NetCTL  IEDB SVMHC  NetCTL SVMHC 
DENV1 33       21*  24       1***  24       1*** 
DENV2 35       29  25       1***  24       2*** 
DENV3 38       25*  25       1***  26       0*** 
DENV4 25       20  23       1***  22       2*** 
All DENV 131       95**  97       4***  96       5*** 
 
Table B.2b.  Counts used to determine RANK measures at top 5% of prediction results between each pair of programs tested for all 
four DENV serotypes individually as well as all serotypes combined (* P<0.05, ** P<0.01, *** P<0.001). 
 
Serotype IEDB NetCTL  IEDB SVMHC  NetCTL SVMHC 
DENV1 15       10  5       0*  5       1 
DENV2 21       14  8       0**  7       2 
DENV3 24       12*  6       1  7       0** 
DENV4 14       7  7       0**  7       2 
All DENV 74       43**  26       1***  26       5*** 
 
